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ABSTRACT 
Elizabeth Ann Phipps 
 
CONSEQUENCES OF TELOMERASE INHIBITION AND TELOMERE 
DYSFUNCTION IN BRCA1 MUTANT CANCER CELLS  
 
Telomere maintenance is a critical component of genomic stability. An 
increasing body of evidence suggests BRCA1, a tumor suppressor gene with a variety 
of functions including DNA repair and cell cycle regulation, plays a role in telomere 
maintenance. Mutations in BRCA1 account for approximately half of all hereditary 
breast and ovarian cancers, and the gene is silenced via promoter methylation and loss 
of heterozygosity in a proportion of sporadic breast and ovarian cancers. The objective 
of this study was to determine whether GRN163L, a telomerase inhibitor, currently in 
clinical trials for the treatment of cancer, has enhanced anti-cancer activity in BRCA1 
mutant breast/ovarian cancer cell lines compared to wild-type cancer cells. BRCA1 
mutant cancer cells were observed to have shorter telomeres and increased sensitivity 
to telomerase inhibition, compared to cell lines with wild-type BRCA1. Importantly, 
GRN163L treatment was synergistic with DNA-damaging drugs, suggesting potential 
synthetic lethality of the BRCA1 cancer subtype and telomerase inhibition  In a related 
study to examine the roles of BRCA1/2 in telomere maintenance, DNA and RNA 
extracted from peripheral blood were used to investigate the age-adjusted telomere 
lengths and telomere-related gene expression profiles of BRCA1 and BRCA2 
individuals compared to individuals who developed sporadic cancer and healthy 
vi 
 
controls. BRCA1 mutation carriers and breast cancer patients showed the shortest 
average telomere lengths compared to the other groups. In addition, distinct genomic 
profiles of BRCA mutation carriers were obtained regarding overexpression of 
telomere-related genes compared to individuals who developed sporadic or familial 
breast cancer. In summary, telomerase inhibition may be a viable treatment option in 
BRCA1 mutant breast or ovarian cancers. These data also provides insights into 
further investigations on the role of BRCA1 in the biology underlying telomere 
dysfunction in cancer development. 
 
       Brittney-Shea Herbert, PhD, Chair 
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
 
Cancer Morbidity and Mortality 
 Despite advances in diagnosis and treatment, cancer remains the second leading 
cause of death in the United States.  The annual economic impact of healthcare for the 
disease is estimated at over $200 billion according to the National Institutes of Health.  
Approximately 500,000 people in the United States will die of cancer this year.  Though 
5-year survival rates for many cancers have improved dramatically since the 1970s, 
treatment of metastatic disease poses significant challenges (American Cancer Society, 
www.cancer.org).     
 Breast cancer is the most commonly diagnosed cancer in women and the second 
leading cause of cancer deaths in women each year, accounting for 14% of overall cancer 
fatalities.  Breast cancer outcomes vary widely depending upon disease stage and 
subtype.  Five-year survival for ductal carcinoma in situ (DCIS), the earliest stage of 
breast cancer (Stage 0), is approximately 93%.  Survival rates go down if cancer has 
spread to one or more lymph nodes at time of detection and, if cancer is detected in 
distant organs or lymph nodes (Stage IV disease), 5-year survival is estimated at 15% 
(American Cancer Society, www.cancer.org).  
 For well over ten years, breast cancer treatment has been determined by tumor 
expression of estrogen (ER), progesterone (PR) and human epidermal growth factor 
receptor 2 (HER2).  Though expression of hormone receptors remains central to breast 
cancer classification and treatment, work by Perou and colleagues in 2000 led to 
breakthroughs in our understanding of the complexity and heterogeneity of the disease.  
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Using cDNA microarray analysis of 65 breast cancer surgical specimens, Perou and 
collaborators revealed five distinct molecular subtypes of disease: basal-like, HER2, 
normal breast-like, luminal A, and luminal B (Perou, Sorlie et al. 2000).  The intrinsic 
subtypes were subsequently demonstrated to be associated with patient outcome, with 
basal-like cancers having the worst overall survival (Sorlie, Perou et al. 2001).  Most 
basal-like cancers lack expression of ER, PR, and HER2 receptors and, as a consequence, 
this subtype does not respond to endocrine therapies and Herceptin®.  In addition, many 
basal-like cancers exhibit germline mutation or sporadic dysfunction in the BRCA1 
(breast cancer 1, early onset) tumor suppressor gene. (Schnitt 2010).    
 The development of breast cancer is as complex as the varied pathology of the 
disease itself.  Lifestyle factors such as weight, alcohol use, contraceptive use, hormone 
replacement therapy, and pregnancy history have all been linked to an increased risk of 
breast cancer.  Other risk modifiers include age, race, breast tissue density, and family 
history of breast cancer. Rates of breast and ovarian cancer are higher among women 
with germline mutations in BRCA1 or BRCA2 tumor suppressor genes (American Cancer 
Society, www.cancer.org), and hereditary breast cancers that develop in BRCA1 carriers 
are often early-onset, particularly aggressive, basal-like, and lack targeted treatment 
options (Holstege, Horlings et al. 2010).   
 The design of therapies specific for hereditary breast cancer is aided by an 
understanding of the molecular contributions of BRCA1 and BRCA2 to maintenance of 
genomic stability.  Biallelic loss of either tumor suppressor facilitates selection of 
additional mutations favoring tumor evolution, and recent evidence suggests loss of a 
single allele of BRCA1 also propagates this process (Konishi, Mohseni et al. 2011).  This 
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work tests the hypothesis that genomic instability after BRCA1 loss occurs, in part, 
through alterations to telomere length and expression of telomere and telomerase-
associated genes.  Targeted therapies must take aim at features, or “hallmarks of cancer” 
tumors depend upon to develop and thrive, and limitless replicative potential fueled by 
telomerase reactivation is one such hallmark (Hanahan and Weinberg 2000; Hanahan and 
Weinberg 2011).  Telomerase is reactivated and functions to maintain telomere length in 
nearly all cancers, and this thesis examines inhibition of telomerase activity in the context 
of BRCA1 deficiency and telomere dysfunction in BRCA mutation carriers. 
 
Telomeres and Cancer 
Telomeres are nucleoprotein structures that cap and protect the ends of linear 
chromosomes in most eukaryotic organisms.  Human telomeres are comprised of 
TTAGGG repeats ending in a single-stranded 3’ G-overhang of approximately18-600 
nucleotides (Moyzis, Buckingham et al. 1988; Zhao, Hoshiyama et al. 2008).  The single-
stranded 3’ overhang loops into the double-stranded DNA forming a T-loop structure 
(Griffith, Comeau et al. 1999).  The “cap” formed at telomeres is comprised of six protein 
shelterin components that interact with DNA and function to prevent telomeres from 
being recognized by cellular DNA repair machinery as double-stranded breaks.  The 
shelterin components TRF1, TRF2, TIN2, TPP1, and RAP1 bind double-stranded 
telomeric DNA, while POT1 binds the 3’ single-stranded overhang.  TRF1, TRF2, and 
POT1 show specificity for binding TTAGGG repetitive DNA (de Lange 2005) (Figure 
1.1).   
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Figure 1.1 Telomeres cap and protect chromosome ends.  
Telomeres are comprised of TTAGGG repeats ending in a single-stranded 
3’ G overhang that forms a t-loop structure.  Telomeres, together with 
shelterin components TRF1, TRF2, TIN2, TPP1, RAP1 and POT1, cap the 
ends of chromosomes and prevent them from being recognized as double-
strand breaks by cellular repair machinery.  Adapted from (Denchi 2009; 
Gu, Bessler et al. 2009) 
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Murine models using conditional deletion of TRF1 and TRF2 demonstrate these 
proteins prevent ATM (ataxia telangiectasia-mutated) and ATR (ATM and Rad3-related)  
signaling, DNA resection, HR (homologous recombination), and both classical (cNHEJ) 
and alternative (altNHEJ) NHEJ (non-homologous end joining) (Sfeir and de Lange 
2012).  Shelterin components are also integral to the formation of telomeric structure.  
Both dominant negative inhibition of TRF2 and RNA interference-mediated knockdown 
of POT1 result in loss of the 3’ G-overhang (van Steensel, Smogorzewska et al. 1998; 
Hockemeyer, Sfeir et al. 2005).  In addition, POT1 is thought to play a role in sequence 
determination at the 5’ end of telomeric DNA (Hockemeyer, Sfeir et al. 2005). 
Due to an inability of standard DNA polymerases to remove the last primer on the 
lagging DNA strand after replication, a phenomenon known as the “end-replication 
problem”, erosion of DNA occurs at chromosome ends with each cell division (Harley, 
Futcher et al. 1990).  Telomeric loss in human leukocytes is estimated to be 
approximately 25 base pairs per year, though higher rates of loss have been reported 
(Muezzinler, Zaineddin et al. 2013).  As such, the repetitive, non-coding DNA at 
telomeres protects critical genes from being lost during replication (Moyzis, Buckingham 
et al. 1988; Levy, Allsopp et al. 1992).  Regardless of the protective barrier telomeres 
provide, the shortening that occurs with each cell division eventually limits the 
replicative lifespan in cells lacking telomerase, the enzyme that synthesizes telomeres, 
and acts as a mitotic clock.  This correlation between telomere length and replicative 
potential is known as the telomere hypothesis (Harley 1991; Harley and Villeponteau 
1995).  Ultimately, telomeric erosion triggers a DNA damage response, growth arrest, or 
apoptosis (Shay and Wright 2005).  
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A DNA damage response at the telomere can also be triggered independently of 
telomere length through loss of shelterin components (Harrington and Robinson 2002). 
With TRF2 disruption, telomere dysfunction and uncapping occurs rapidly and without 
concurrent loss of telomeric DNA (Karlseder, Broccoli et al. 1999).  Conversely, 
inhibition of telomerase, the enzyme responsible for synthesizing telomeric DNA, leads 
to gradual telomere shortening.  The DNA damage response triggered by disruption of 
shelterin components differs from the damage response triggered by progressive telomere 
shortening not only in terms of timing, but also in terms of molecular response.  For 
instance, NHEJ following TRF2 deletion is Ligase 4 (Lig4)-dependent, while telomere 
shortening triggers Lig4-independent NHEJ (Rai, Zheng et al. 2010).      
Both p53-dependent and p53-independent mechanisms of telomere dysfuction 
have been demonstrated using inhibition of shelterin components or depletion of 
telomerase.  The DNA damage response and subsequent growth arrest and apoptosis 
triggered by dominant-negative disruption of endogenous TRF2 are p53 dependent 
(Karlseder, Broccoli et al. 1999), though a p53-independent mechanism has been 
demonstrated in a p53 mutant background (van Steensel, Smogorzewska et al. 1998).  
Both responses result in rapid chromosomal fusions and growth arrest (Karlseder, 
Broccoli et al. 1999; van Steensel, Smogorzewska et al. 1998). Mice deficient in mTerc, 
the protein component of the telomerase enzyme, show defects in cell proliferation, 
wound healing, and p53-dependent apoptotic loss of germ cells resulting in sterility 
(Chin, Artandi et al. 1999).  Though depletion of p53 restores fertility (Chin, Artandi et 
al. 1999), late generation mTerc/p53 -/-mice show an increased incidence of lymphomas 
and teratocarcinomas compared to mTerc -/- mice, providing the first direct link between 
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telomere dysfunction and cancer (Chin, Artandi et al. 1999; Artandi, Chang et al. 2000; 
Rudolph, Millard et al. 2001). 
Short, dysfunctional telomeres are a feature of cancer cells (Maser and DePinho 
2002).  Telomere shortening or uncapping contributes to genomic instability and 
tumorigenesis through promoting chromosomal fusions and breakages at unprotected 
chromosome ends (Artandi, Chang et al. 2000; Gunes and Rudolph 2013).  These 
rearrangements may ultimately result in deregulation of critical genes that directly drive 
cancer, with subsequent selection of alterations that favor growth and metastasis (Gunes 
and Rudolph 2013).  Evidence from telomerase-deficient mice and from studies of human 
disease suggest telomere dysfunction plays a role in the early stages of carcinogenesis 
(Chin, Artandi et al. 1999; Rudolph, Chang et al. 1999; Artandi, Chang et al. 2000; 
Rudolph, Millard et al. 2001; Feldser, Hackett et al. 2003; Meeker and Argani 2004; 
Tanaka, Abe et al. 2012).  In support of this notion, mutations in hTERC cause autosomal 
dominant Dyskeratosis Congenita (DKC), a disease characterized by bone marrow 
failure, telomere shortening and increased incidence of cancer (Vulliamy, Marrone et al. 
2001).  Moreover, telomere dysfunction followed by reactivation of telomerase promotes 
tumor development in mice, providing further support for the role of telomere 
dysfunction early in tumorigenesis (Begus-Nahrmann, Hartmann et al. 2012). 
 
Telomerase and Cancer  
Telomerase is an enzyme comprised of a C-rich RNA (termed hTR for humans 
and encoded by the TERC gene) with a template region for use by the catalytic reverse  
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Figure 1.2. The telomerase enzyme complex. 
With its C-rich RNA template component and catalytic subunit containing 
reverse transcriptase activity, the telomerase enzyme is specifically equipped 
for synthesizing telomeres.  Dyskerin, a highly conserved nucleolar protein 
that modifies newly synthesized ribosomal RNAs, associates with telomerase 
and is a critical component of telomere maintenance.  Mutations in the gene 
that encodes dyskerin, DKC1, lead to X-linked Dyskeratosis Congenita (DC), 
while mutations in TERC, TERT, and TIN2 [not shown] have been identified 
in the autosomal dominant form of the DC disease.  Adapted from (Dokal 
2011; Goldblatt 2009; Harley 2008). 
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transcriptase protein component (termed hTERT and encoded by the TERT gene located 
on the short arm of chromosome 5)  (Feng, Funk et al. 1995; Nakamura, Morin et al. 
1997).  Unlike standard replicative DNA polymerases, telomerase is specifically 
equipped for synthesizing telomeres.  The C-rich RNA component acts as a template for 
addition of telomeric repeats using the hTERT reverse transcriptase (Chan and Blackburn 
2004) (Figure 1.2).  The first clues of a link between telomerase expression, telomere 
length maintenance, and cellular immortalization came from studies of SV40-transformed 
human embryonic kidney cells.  While most cells showed genomic instability and died 
after a finite number of population doublings, approximately 1 in 1x10
7 
cells acquired 
telomerase activity and was able to divide indefinitely (Counter, Avilion et al. 1992).  
Others subsequently demonstrated that ectopically introducing telomerase in normal, 
telomerase-negative cells extends telomeres and allows cells to grow indefinitely 
(Bodnar, Ouellette et al. 1998).  Despite conferring limited replicative capacity, the 
addition of telomerase does not cause tumorigenicity.  To become tumorigenic, additional 
factors are required, specifically large SV40 T-antigen and oncogenic RAS (Hahn, 
Counter et al. 1999).   
Telomerase is tightly regulated, with expression levels maintained low, and its 
activity off, in most normal cells.  Telomerase is expressed at low levels in stem cells and 
germ cells to allow continued proliferation of these tissues.  This finding holds 
significance in that stem cells are hypothesized to play a role in cancer initiation and 
maintenance (Gunes and Rudolph 2013).  Without telomerase, fibroblasts are limited to 
approximately 50-70 population doublings, an observation first described by Leonard 
Hayflick and termed the Hayflick Limit (Hayflick 1979).  After this finite period of   
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Figure 1.3. Telomerase functions to maintain telomere length. 
Cells without telomerase undergo a finite number of population doublings (approximately 
50-70 population doublings in fibroblasts) before reaching replicative (cellular) 
senescence. In cells without telomerase, once telomeres reach a critically short level 
DNA damage or apoptotic responses may be triggered.  Cells with telomerase activity, 
such as germ cells and stem cells, can continue growing and dividing indefinitely 
allowing for continued repopulation of these tissues.  In cancer development, cells are 
thought to undergo a number of population doublings in the absence of telomerase, 
leading to telomere shortening.  Ultimately, a rare cell acquires telomerase activity and is 
able to continue growing and dividing indefinitely despite having short, dysfunctional 
telomeres.  The vast majority of cancers utilize telomerase to achieve unlimited 
replicative potential.  Adapted from (Goldblatt 2009; Harley 2008). 
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growth, cells reach replicative senescence; this cessation of growth correlates with 
telomere shortening (Allsopp, Vaziri et al. 1992) (Figure 1.3).  Restriction and tight 
regulation of telomerase expression acts as a tumor suppressive mechanism by preventing 
uncontrolled growth and division.  The importance of telomerase in cancer development 
is illustrated by the observation that tumor suppressors and oncogenes deregulated in 
cancer affect telomerase expression in ways that cooperatively promote tumorigenesis.  
For example, oncogene c-Myc is often amplified in cancer and is an activator of hTERT 
(Greenberg, O'Hagan et al. 1999).  Aurora A kinase, a G2/M cell cycle regulator 
commonly amplified in epithelial malignancies (Fu, Bian et al. 2007), positively regulates 
c-Myc, and thus stimulates telomerase activity (Yang, Ou et al. 2004).  BRCA1, a tumor 
suppressor gene lost in a proportion of hereditary breast and ovarian cancers, inhibits 
hTERT transcription through negative regulation of c-Myc (Li, Lee et al. 2002; Zhou and 
Liu 2003).  The tradeoff of tight regulation of telomerase activity in normal cells is 
telomere shortening and, ultimately, telomere dysfunction, both of which are known to 
contribute to aging and malignancy (Harley 2008). 
Approximately 90% of cancers utilize telomerase to achieve unlimited replicative 
potential (Shay and Bacchetti 1997), and expression of telomerase is linked to tumor 
aggressiveness and poor outcome (Sanders, Drissi et al. 2004; Lamy, Goetz et al. 2012).  
The remaining 10% of cancers, typically soft tissue sarcomas (Henson, Neumann et al. 
2002), activate an alternative lengthening of telomeres (ALT) pathway thought to occur 
via homologous recombination (Greenberg 2005).  When telomerase is reactivated in the 
context of telomere dysfunction in cancer cells, it contributes not only to limitless 
replicative potential and maintenance of telomeres, but also to prevention of apoptosis in 
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cells harboring genomic instability.  hTERT regulates a number of genes responsible for 
DNA repair and cell cycle regulation, and recruits initiation factors to sites of DNA 
damage (Cao, Li et al. 2002; Sharma, Gupta et al. 2003; Lamy, Goetz et al. 2012).  
Through facilitating DNA repair and preventing apoptosis, hTERT can contribute to 
chemotherapy resistance (Sharma, Gupta et al. 2003; Lamy, Goetz et al. 2012). 
     
Targeting Telomerase as a Therapeutic Strategy in Cancer 
 Telomerase is an attractive target in cancer for a variety of reasons.  Namely, 
telomerase activity is required for almost all tumors to achieve limitless replicative 
potential.  The genes that encode telomerase and its associated factors are non-redundant, 
and this has significant therapeutic implications in that cells are less likely to develop 
resistance to inhibitors.  In addition, there are differences in telomerase expression and 
telomere length between most normal and cancer cells.  These factors contribute to what 
has been described as a broad therapeutic window for targeting telomerase (Harley 2008).  
Various strategies have been employed to target telomerase, including gene therapy, 
active G-quadraplex stabilizers, telomerase immunotherapy, and direct enzyme inhibition 
of telomerase (Harley 2008).  Using a rational oligonucleotide approach, Geron 
Corporation developed a thio-phosphoramidate antisense oligonucleotide telomerase 
inhibitor, termed GRN163, and Herbert et al. subsequently demonstrated that a lipid 
conjugation improved cellular uptake and efficacy (lipid conjugation designated by an 
“L”, GRN163L) (Figure 1.4) (Herbert, Gellert et al. 2005).  GRN163L, also known as 
imetelstat, is a telomerase template antogonist that binds complementary to the template  
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Figure 1.4. GRN163L structure. 
GRN163L is a telomerase template (hTR) antagonist, consisting of a 13-mer thio-
phosphoramidate oligocucleotide backbone covalently bound to a palmitoyl lipid 
moiety.  The lipid moiety facilitates cellular uptake Adapted from (Roth, Harley et al. 
2010; Goldblatt 2009; Harley 2008). 
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Figure 1.5. GRN163L binds complementary to the RNA template of hTR and 
prevents telomerase from binding to telomeric DNA.   
GRN163L treatment leads to telomerase inhibition, telomere shortening, cellular 
senescence, and apoptosis.  Adapted from (Goldblatt 2009; (Harley 2008) 
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sequence in hTR, thus preventing telomerase from binding to and extending the telomere 
(Figure 1.5).  One advantage of oliognuclotides is that they are polyanionic, and are 
therefore less likely to be substrates of multidrug resistance mechanisms (Harley 2008).  
Work by our laboratory and others has demonstrated GRN163L’s efficacy in a wide 
range of cancer cell lines and in combination with ionizing radiation and 
chemotherapeutic agents, including paclitaxel, doxorubicin, trastuzumab, and inhibitors 
of ATM kinase (Djojosubroto, Chin et al. 2005; Agarwal, Pandita et al. 2008; Goldblatt, 
Erickson et al. 2009; Goldblatt, Gentry et al. 2009; Tamakawa, Fleisig et al. 2010).  
GRN163L has been in Phase I/II clinical trials for a variety of cancer types such as lung, 
brain, and breast cancers, including a Phase I trial for refractory HER2 positive breast 
cancers (clinicaltrials.gov, NCT00732056).  
 Loss of viability following telomerase inhibitor treatment correlates with initial 
telomere length.  One potential concern with telomerase inhibition is the time required to 
allow telomeres to reach a critically short level after onset of treatment.  Importantly, 
most cancer cells already have relatively short telomeres, as telomere shortening and 
dysfunction usually precede telomerase reactivation in cancer.  Reactivation of 
telomerase then serves to maintain, but not necessarily to extend, telomere length, 
allowing sustained proliferation of cancer cells harboring genomic instability and 
telomere dysfunction.  Nevertheless, finding a good target population is critical for 
achieving optimal therapeutic response to telomerase inhibition, and cancers with very 
short telomeres and a high degree of genomic instability might be particularly sensitive.  
Recent evidence suggests that telomeres in individuals with BRCA1/2 breast cancers are 
shorter than telomeres in individuals with sporadic breast cancers (Martinez-Delgado, 
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Yanowsky et al. 2011).  Telomere dysfunction has been reported in cells following 
BRCA1 knockdown, and other links between BRCA1 and telomere maintenance have 
been reported and are described in the next section.  Furthermore, ALT is thought to 
occur via HR, so BRCA1 deficient cells, which lack this repair function as described in a 
subsequent section, may be less inclined to activate ALT and contribute to telomerase 
inhibitor resistance (Greenberg 2005).  Inhibiting telomerase in the context of BRCA1 
deficiency may be synergistic due not only to the role of BRCA1 in telomere 
maintenance, but also due to the reported role of telomerase expression in facilitating 
double-strand break repair through affecting chromatin remodeling and ATM activation 
(Masutomi, Possemato et al. 2005).   
   
Hereditary Breast and Ovarian Cancers   
Inherited mutations in BRCA1 or BRCA2 tumor suppressor genes account for the 
vast majority of hereditary breast and ovarian cancers with a known genetic cause, and a 
proportion of the remaining hereditary cases may be attributed to mutations of genes 
within the same pathway (Ford, Easton et al. 1998; Walsh, Casadei et al. 2006; Kuusisto, 
Bebel et al. 2011) (Figure 1.6).  Mutations in BRCA1 are inherited in an autosomal 
dominant fashion and are highly penetrant, with epidemiologic studies suggesting a 
lifetime risk of breast cancer greater than 80% (Welcsh and King 2001).  Mary-Claire 
King used linkage studies and mapped BRCA1 to chromosome 17q21 in 1990 (Hall, Lee 
et al. 1990).  The gene was subsequently cloned in 1994 and controversially patented for 
diagnostic purposes in 1998 by Myriad Genetics (Miki, Swensen et al. 1994; US Patent 
5747282).   
17 
 
  
Figure 1.6.  Known genetic causes of hereditary breast and ovarian cancer in a 
convergent DNA repair pathway. 
The majority of hereditary breast and ovarian cancers are attributable to inherited 
mutations in BRCA1 or BRCA2.  In both hereditary breast and ovarian cancer (with the 
exception of ATM mutation in ovarian cancer), germline mutations have also been 
identified in all genes pictured in the homology-directed double-strand break repair 
pathway .  Additionally, germline mutations in mismatch repair genes (not pictured) have 
been implicated in hereditary ovarian cancer (2003; Elstrodt, Hollestelle et al. 2006; 
Walsh and King 2007; Pennington and Swisher 2012).  
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Figure 1.7.  Common pathogenic mutations in BRCA1 and their functional 
consequences.   
Thousands of pathogenic mutations and variants of unknown significance have been 
identified in the 24 exons of BRCA1 and within intronic regions, with differing 
functional consequences.  The majority of disease-causing mutations result in 
frameshifts and protein inactivation.  185delAG and 5382insC are founder mutations in 
the Ashkenazi Jewish population, while the 2800del AA, 2594delC, and 5396+1G>A 
are common among northern European populations in Scotland, Ireland, Scandanavia, 
Denmark, Belgium and the Netherlands.  Modified from (Mark, Liao et al. 
2005)www.cancer.gov).  
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The BRCA1 gene contains 24 exons, and mutations and variants are found a 
long the entire coding region of BRCA1 and within intronic sequences (Ferla, Calo et al. 
2007), with a range of functional consequences (Figure 1.7).  The majority of deleterious 
mutations are point mutations and small insertions/deletions resulting in frameshifts and 
protein inactivation, though genomic rearrangements missed by conventional sequencing  
have also been reported (Mazoyer 2005).  Nearly all of the genomic rearrangements 
reported in BRCA1 (26 out of 29) are due to unequal homologous recombination, 
hypothesized to occur frequently due to the high density of Alu repeats within the gene 
(Welcsh and King 2001; Mazoyer 2005).  Thousands of mutations and variants, 
sometimes rare, and of unknown biological and clinical significance, have been identified 
in BRCA1.  Specific pathologic mutations or rearrangements in the gene occur at high 
frequency, however, due to founder effects in certain ethnic groups, such as Ashkenazi 
Jews and individuals with ancestors from Iceland, Norway, Sweden and Finland.  Among 
Ashkenazi Jews, it is estimated that 1% of the population harbors the BRCA1 185delAG 
mutation, while 0.13% has a BRCA1 5382insC mutation (Roa, Boyd et al. 1996; Ferla, 
Calo et al. 2007).  Both mutations are deleterious, and carry a nearly 70% lifetime risk of 
breast cancer.  Ovarian cancer risk for these particular mutations is lower (14% for the 
185delAG mutation and 33% for the 5382insC mutation) (Satagopan, Boyd et al. 2002; 
Antoniou, Pharoah et al. 2005; Ferla, Calo et al. 2007).   
A clinician ordering the BRCA1 diagnostic test employed by Myriad Genetics, 
Inc. has the option to order a single site mutation test, a test for a panel of specific 
founder mutations, or a full sequencing test.  The full sequencing test also checks for 
three common rearrangements within the BRCA1 gene.  Myriad classifies a variation or 
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mutation in BRCA1 as a polymorphism, favor polymorphism, variant of uncertain 
significance, suspected deleterious or deleterious mutation (Jennifer Saam, genetic 
counselor at Myriad Genetics, personal communication).  Clinicians and genetic 
counselors use results from this test to make recommendations about prevention, though 
in the event of a “variant of uncertain significance” or “suspected deleterious” result, the 
guidelines are less straightforward.  Nevertheless, mutational testing has significant 
consequences for individuals of unknown, or moderate to high probability of developing 
cancer, as current recommendations for risk reduction are prophylactic mastectomy and 
oophorectomy (Daly, Axilbund et al. 2010).  Though deemed worthwhile for high-risk 
individuals, this preventative strategy has been criticized by some for its lack of clear, 
consistent guidelines and the potential for overtreatment it invites in lower-risk 
individuals (Wainberg and Husted 2004; Domchek, Friebel et al. 2010). 
Patients diagnosed with BRCA1 cancer currently follow a standard adjuvant 
chemotherapy regimen, though increased understanding of the role of BRCA1 in 
homologous recombination has spawned clinical trials incorporating platinum and 
anthracycline-based chemotherapy and inhibitors of poly (ADP-ribose) polymerase 
(PARP) (Trainer, Lewis et al. 2010; Tutt, Robson et al. 2010).  Not all BRCA patients 
respond to PARP inhibitors, however, and toxicity to chemotherapy remains a challenge 
(Maxwell and Domchek 2012).  BRCA1 breast cancers are frequently classified as triple 
negative breast cancer (TNBC) due to their lack of expression on hormone receptors ER, 
PR, and HER2.  Tumors in this subtype are typically basal-like, poorly differentiated, 
highly aneuploid, aggressive, and carry a poor prognosis (van der Groep, van der Wall et 
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al. 2011).  For these reasons, improved targeted therapies and understanding of the 
molecular processes central to BRCA1 in tumorigenesis are paramount.   
In an effort to understand phenotype and predict clinical outcome among 
hereditary breast cancers, Price and colleagues used comparative genomic hybridization 
(CGH) to study a group of early-onset breast cancer patients and found all but one 
BRCA1 tumor clustered in a group which also included tumors phenotypically similar to 
BRCA1 tumors, but in which no BRCA1 mutation was detected.  This group was high-
grade triple negative, showed a high mitotic rate, gain of 19p, and loss of 5q14-22 and 
4q28-32.  In contrast, tumors from BRCA2 individuals were not as clearly defined, and 
were spread all over the six phenotypic groups (Price, Armes et al. 2006).  The 
differences in pathology of BRCA1 compared to BRCA2 tumors may be due to the 
function of BRCA1 as a gatekeeper and sensor implicated in a wide-range of processes 
related to safeguarding genomic integrity, while BRCA2 appears to have a more limited 
and direct role in DNA repair (van der Groep, van der Wall et al. 2011).  
 
BRCA1: Roles in Cancer and Telomere Maintenance 
BRCA1 has a wide range of functions related to safeguarding genomic integrity, 
including DNA repair, cell cycle regulation, transcription, and chromatin remodeling 
(Figure 1.8).  To accomplish these activities, BRCA1 forms a variety of protein 
complexes, including a heterodimer with BARD1.  The BRCA1/BARD1 heterodimer 
associates with RNA polymerase II, an mRNA synthesizing enzyme.  When bound to 
BARD1, the N-terminus of BRCA1 has ubiquitin ligase activity  
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Figure 1.8.  BRCA1 is hypothesized to contribute to telomere maintenance 
through its many functions in maintaining genomic stability. 
BRCA1 has been implicated in cell cycle checkpoint regulation, transcriptional 
regulation, and chromatin remodeling.  In addition, BRCA1 is involved either directly 
or indirectly in homologous recombination, non-homologous end-joining, nucleotide 
excision repair, and base excision repair.  Together, these functions of BRCA1 are 
hypothesized to contribute to telomere maintenance. Adapted from (Kennedy, Quinn 
et al. 2004). 
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(Hashizume, Fukuda et al. 2001), and ubiquinates BRCA1 itself, histone proteins, and 
FANCD2 and p53, though the biological significance of these reactions is unknown 
(Parvin 2004).  In addition, BRCA1 complexes with a number of repair factors (termed 
BASC, or BRCA1-associated surveillance complex) and with chromatin remodeling 
factors.  The C-terminus of BRCA1 contains BRCT (BRCA1 C terminus domain) repeats 
which function to facilitate interactions between BRCA1 and other repair proteins and 
cell cycle regulators (Yu, Chini et al. 2003).  BRCA1 expression is developmentally 
regulated and positively correlated with estrogen expression, and this observation is 
hypothesized to explain why individuals with BRCA1 mutations develop breast and 
ovarian cancers rather than other cancer types (Welcsh and King 2001).  Evidence of this 
link comes from a recent study demonstrating BRCA1 has a role in nucleotide excision 
repair (NER) of bulky adducts, which are byproducts of estrogen metabolism (Pathania, 
Nguyen et al. 2011).  In addition, estrogen activates ERK signaling to stimulate rapid 
proliferation of the breast epithelium during puberty, and this growth is negatively 
regulated by BRCA1 (Razandi, Pedram et al. 2004).  In an individual harboring an 
inactivating germline mutation in BRCA1, the stress and DNA damage produced by this 
growth likely puts excessive strain on the repair machinery, allowing for accumulation of 
additional mutations and cancer development (Welcsh and King 2001).   
In addition to the aforementioned role of BRCA1 in NER, BRCA1 is also 
involved in base excision repair (BER) (Saha, Smulson et al. 2010) and repair of double-
strand breaks by both error-free homologous recombination (HR) (Moynahan, Chiu et al. 
1999) and error-prone non-homologous end joining (NHEJ) (Zhong, Chen et al. 2002) 
mechanisms.  As telomeres function to protect chromosome ends from being recognized 
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as double-strand breaks, it is perhaps not surprising that many DNA damage response 
proteins have dual roles in the response to telomere dysfunction.  Titia de Lange first 
described telomere-dysfunction-induced foci (TIFs) containing DNA damage response 
factors 53BP1, -H2AX, Rad17, ATM, and Mre11 (Takai, Smogorzewska et al. 2003).  
Either HR or NHEJ is activated at dysfunctional telomeres, and each of these pathways 
has different cellular consequences, with HR leading to activation of ALT and telomere 
lengthening, and NHEJ leading to chromosomal fusions (Gunes and Rudolph 2013).  
BRCA1 has a role in each of these repair pathways, and interacts directly or indirectly 
with the components found in TIFs (Deng and Brodie 2000; Welcsh and King 2001; 
Rauch, Zhong et al. 2005), though its role in response to telomere dysfunction is unclear 
at present. 
BRCA1 has been described as a “gatekeeper” and is thought to integrate sensors 
and transducers from multiple repair pathways to facilitate and coordinate the cellular 
response to genomic insults.  In this way, BRCA1 is postulated to mediate the ability of 
ATM and ATR sensor kinases to phosphorylate downstream target transducers (Foray, 
Marot et al. 2003).  In response to double-strand breaks, H2AX is rapidly phosphorylated 
by ATM and forms foci at sites of DNA damage.  BRCA1 is present at these foci many 
hours before other DNA repair factors, and is thought to modify chromatin structure to 
facilitate recruitment of other damage repair proteins to the site (Welcsh and King 2001).  
BRCA1 also has broad cell cycle influences through regulation of a multitude of cell 
cycle proteins (Wang, Shao et al. 1997), including induction of p21 leading to G1/S arrest 
(Somasundaram, Zhang et al. 1997).  In addition, BRCA1 null cells are defective in the 
G2/M checkpoint following DNA damage (Larson, Tonkinson et al. 1997).  
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Numerous repair proteins have overlapping roles not only in the response to 
telomere dysfunction but also in the prevention of telomere dysfunction (referred to here 
as telomere maintenance) through interactions with shelterin components and effects on 
telomere length, some incompletely understood.  One study suggests HR directly affects 
telomere maintenance through generating t-loop deletions of telomeric DNA.  The 
authors demonstrate this effect using a mutant TRF2 that blocked NHEJ.  Interestingly, 
the same t-loop deletions were also seen in normal, unperturbed cells, suggesting a role 
for HR in normal telomere maintenance (Wang, Smogorzewska et al. 2004).  The 
interplay between telomere maintenance and HR signaling is evident from a study 
demonstrating that TRF2 binds to and inhibits signaling from ATM (Karlseder, Hoke et 
al. 2004).  ATM was initially found to have a role in telomere maintenance through 
studies of patients with ataxia telangiectasia (A-T), a rare, neurodegenerative disease 
caused by inherited mutations in ATM.  The disease is characterized by various 
neurologic and immune problems, accelerated aging, and an increased risk of cancer 
(Metcalfe, Parkhill et al. 1996).  Some of these manifestations may be explained by the 
observation that A-T individuals have accelerated telomere shortening and extra-
chromosomal telomeric DNA (Metcalfe, Parkhill et al. 1996; Hande, Balajee et al. 2001).  
Mutations in NBS1, another crucial player in double strand break repair, lead to 
Nijmegen breakage syndrome and short telomeres (Ranganathan, Heine et al. 2001).  
NBS1, in conjunction with Mre11 and Rad50, form a repair complex (termed the MRN 
complex) that associates with TRF2 and telomeres in a cell-cycle-regulated manner (Zhu, 
Kuster et al. 2000).  In double-strand break repair, BRCA1 forms a complex with MRN 
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and another factor, CtIP (C-Terminal Binding Protein Interacting Protein), to facilitate 
generation of single-stranded DNA needed for HR resection (Chen, Nievera et al. 2008). 
Rad51, along with BRCA2, are additional factors with dual roles in double-strand 
break repair and telomere maintenance.  Rad51 (-/-), p53 (-/-) mouse embryonic 
fibroblasts (MEFs) show telomere shortening and telomeric fusions compared to p53(-/-) 
or wild-type MEFs (Tarsounas, Munoz et al. 2004), and BRCA2 has a role in loading 
Rad51 onto the telomere to facilitate telomere replication and capping (Badie, Escandell 
et al. 2010).  PARP1, a component of the BER pathway, modifies TRF2 and affects its 
binding to telomeric DNA (Gomez, Wu et al. 2006).  Recruitment of PARP1 and 
modification of TRF2 occur preferentially at eroded telomeres, and are thought to act as a 
protective mechanism against telomeric fusions (Gomez, Wu et al. 2006).   
 
Overall Objectives and Hypothesis 
Evidence of telomere defects in BRCA1 null cells and patients has been reported 
in multiple studies (Al-Wahiby and Slijepcevic 2005; Cabuy, Newton et al. 2005; French, 
Dunn et al. 2006; McPherson, Hande et al. 2006; Martinez-Delgado, Yanowsky et al. 
2011), though the mechanism is unknown at present.  As BRCA1 is an integral part of the 
aforementioned pathways through interactions with the repair factors described, it is 
possible that BRCA1 affects telomere maintenance by acting either directly at the 
telomere or indirectly through bringing critical factors to sites of telomere dysfunction as 
it does to sites of DNA damage.  In addition, BRCA1 could affect telomere maintenance 
by halting the cell cycle to allow for repair of dysfunctional telomeres.  Thus, BRCA1 
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may be important both for telomere maintenance and for preventing accumulation of 
mutations and persistence of genomic instability after telomere dysfunction.  
The goals of this project were to better understand the effects of telomerase 
inhibition in the context of BRCA1 deficiency and the contributions of BRCA1 to 
telomere maintenance.  This thesis specifically addressed the following hypotheses: 
1. BRCA1 mutant cell lines are more sensitive to telomerase inhibition 
compared to BRCA1 wild-type cell lines due shorter telomere lengths at 
baseline, an increased rate of telomere shortening after telomerase inhibition, 
and persistence of DNA damage owing to the roles of BRCA1 in DNA repair, 
cell cycle regulation, and telomere maintenance.  
2. BRCA carriers have shorter average telomere lengths at baseline relative to 
other cancer subtypes, a factor predisposing them to cancer development. 
3. BRCA carriers show deregulation of telomere-associated and telomere-
proximal genes relative to individuals who developed sporadic or familial 
breast cancer. 
Toward addressing the hypotheses presented in this thesis, a variety of molecular 
and cellular biology techniques were used to access BRCA1 mutant and BRCA1 wild-
type cell lines on the basis of BRCA1 expression levels, baseline telomerase activity 
levels, and baseline telomere length.  In addition, survival assays and 
immunofluorescence were used to determine functionality of BRCA1 in the two isogenic 
cell line pairs used for the majority of the cell culture experiments.  Telomerase activity 
was inhibited pharmacologically using GRN163L or a control mismatch (MM) 
oligonucleotide.  Consequences of telomerase inhibition were studied following 
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GRN163L treatment at various timepoints using telomerase activity, cell survival, cell 
proliferation, telomere length, and expression of -H2AX as endpoints.  In addition, 
telomere length measurements and gene expression profiles were accessed in BRCA1 
and BRCA2 carrier individuals to determine contributions of loss of a single copy of 
BRCA1 or BRCA2 to telomere dysfunction and tumorigenesis. 
  Significance 
Hereditary breast cancers do not have targeted treatment options, largely due to a 
lack of firm understanding of the molecular features and pathogenesis that differentiate 
BRCA1 cancers from other cancer subtypes.  Determining the contributions of BRCA1 
and telomere maintenance to malignant transformation can facilitate the quest for 
personalized medicine in BRCA patients, and also shed light on the as yet undetermined 
relationship among BRCA1, telomeres, and shelterin components.  As telomerase is 
activated in the majority of cancers, this work has the potential to impact studies of not 
only hereditary breast cancer, but of a wide range of malignancies that contribute to the 
global burden of disease.    
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CHAPTER TWO 
BRCA1 MUTANT CELLS EXHIBIT ENHANCED SENSITIVITY TO GRN163L 
 
Abstract 
BRCA1 is a tumor suppressor gene with a variety of functions related to 
safeguarding genomic integrity.  Telomere maintenance is a critical component of 
genomic stability, and an increasing body of evidence suggests BRCA1 plays a role in 
this process.  The objective of this study was to determine whether GRN163L, a 
telomerase template antagonist currently in clinical trials, has enhanced activity in 
BRCA1 mutant breast/ovarian cancer cell lines compared to BRCA1 wild-type 
breast/ovarian cancer cell lines.  We found differences among the cell lines used in this 
study in terms of baseline telomere length, but not baseline telomerase activity.  BRCA1 
mutant cell lines showed decreased clonogenic survival capacity following 3-week 
treatment with GRN163L.  In addition, GRN163L caused telomere shortening over a 3- 
or 6-week period, but no changes in cell cycle distribution.  We found increased -H2AX 
protein expression following 3-week GRN163L treatment in UWB1.289 ovarian cancer 
and HCC1937 pBp breast cancer BRCA1 mutant cell lines relative to their BRCA1wt 
counterparts.  Similarly, immunofluorescence for -H2AX revealed an increase in -
H2AX positive cells in UWB1.289 versus UWB1.289+BRCA1 cells following 1-week 
GRN163L treatment.  Six-week pretreatment and removal of GRN163L, following by 
addition of cisplatin for 72 hours, augments the action of cisplatin in both UWB1.289 and 
UWB1.289+BRCA1 cell lines.  The combination of GRN163L and doxorubicin added 
simultaneously was synergistic at the majority of concentration combinations tested in 
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HCC1937 and HCC1937+BRCA1 cell lines.  In summary, this work provides insight into 
the mechanism behind GRN163L action in BRCA1 mutant and wild-type cells and 
suggests telomerase inhibition used alone or in combination with DNA damaging agents 
may be a viable treatment option for this patient population. 
 
Introduction 
Telomeres are nucleoprotein structures that cap the ends of linear chromosomes.  
Telomeres consist of DNA repeat sequences (TTAGGG in humans) and act as sacrificial 
DNA buffers that are lost with each cell division due to the end replication problem 
(Moyzis, Buckingham et al. 1988; Levy, Allsopp et al. 1992).  Regulation of telomere 
length is crucial in maintaining genomic stability, with critically short telomeres leading 
to telomere uncapping, end-to-end fusions, activation of the DNA damage response, and 
cell cycle arrest (O'Sullivan and Karlseder 2010).  Short, dysfunctional telomeres are a 
feature of cancer cells (Maser and DePinho 2002). 
Telomeres are maintained by telomerase, a tightly regulated enzyme with 
expression levels maintained off in most normal cells but reactivated in cancer cells to 
maintain telomere length (Knight and Flint 2000).  Telomerase activity and telomere 
maintenance contribute to the unlimited replicative potential of cancer cells, which is a 
hallmark of cancer (Hanahan and Weinberg 2011).  The necessity of telomerase activity 
for survival of most cancer cells makes it an attractive therapeutic target.  Telomerase 
template antagonist GRN163L is currently in clinical trials for use in combination with 
chemotherapeutic agents in multiple cancer types, including breast cancer 
(www.clinicaltrials.gov). 
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Mutations in the BRCA1 tumor suppressor gene account for approximately half of 
all hereditary breast and ovarian cancers, and the gene is silenced via promoter 
methylation and loss of heterozygosity in a proportion of sporadic breast and ovarian 
cancers (Honrado, Benitez et al. 2005).  BRCA1 functions are still being elucidated, 
including its potential roles in regulation of cellular senescence and in telomere function.  
Increased expression of BRCA1 interacting partners has been reported as cell lines 
become immortalized.  In addition, post-stasis (post stress-induced senescence) human 
mammary epithelial cells (HMECs) with p16 silenced show BRCA1 localization to the 
nucleus, providing evidence of a role for BRCA1 in the immortalization process (Li, Pan 
et al. 2007).  Current evidence suggests BRCA1 exerts a negative regulatory effect on 
telomerase activity through inhibition of c-Myc, a proto-oncogene capable of telomerase 
activation (Wang, Zhang et al. 1998; Greenberg, O'Hagan et al. 1999; Zhou and Liu 
2003).  This observation is supported by cell culture studies using overexpression of 
exogenous BRCA1 in human breast and prostate cancer cell lines (Xiong, Fan et al. 
2003).   
The role of BRCA1 in determining telomere length is not well understood at 
present.  Some evidence suggests knockdown of BRCA1 in cell lines increases average 
telomere length but may result in more unstable telomeres compared to BRCA1 wild-
type cell lines (Ballal, Saha et al. 2009).  These findings are supported by work showing a 
dominant negative BRCA1 truncation mutant (trBRCA) led to an increase in telomere 
length in telomerase positive human mammary epithelial cells (French, Dunn et al. 2006).  
Work from another group, however, reports the opposite relationship between BRCA1 
and telomere length, with BRCA1, p53-null murine T cells exhibiting shorter telomeres 
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as compared to BRCA1 and p53 wild-type cells (McPherson, Hande et al. 2006).  In 
addition, data from patient populations suggests shorter telomeres in BRCA1 mutation 
carriers, a feature thought to contribute to their predisposition to cancer development 
(Martinez-Delgado, Yanowsky et al. 2011).  Similarly, the reported reduced telomere 
length in precancerous gastric lesions compared to normal tissue is correlated with 
overexpression of telomeric proteins and cytoplasmic export of BRCA1, suggesting 
mislocalization of BRCA1 may play a role in regulation of telomere length (Hu, Zhang et 
al. 2010). 
The objective of this study was to determine whether GRN163L (imetelstat) has 
enhanced activity in BRCA1 mutant breast/ovarian cancer cell lines compared to BRCA1 
wild-type breast/ovarian cancer cell lines.  We found differences among the cell lines 
used in this study in terms of baseline telomere length, and observed enhanced sensitivity 
to GRN163L in BRCA1 mutant cell lines compared to their BRCA1 wild-type 
counterparts.  This sensitivity was coupled with increased expression of DNA damage 
marker -H2AX.  In addition, we demonstrated GRN163L treatment acts synergistically 
with DNA-damaging agents.  This work provides insight into the mechanism behind 
GRN163L action in BRCA1 mutant and wild-type cells and suggests telomerase 
inhibition used alone or in combination with DNA damaging agents may be a viable 
treatment option for this patient population. 
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Results 
BRCA1 mutant and wild-type cell line panel exhibits differences in baseline telomere 
length and BRCA1 levels 
We utilized a panel of breast (n=6) and ovarian (n=2) cancer cell lines containing 
wild-type BRCA1 or various somatic or germline mutations from different regions 
throughout the full-length BRCA1 gene (Table 2.1).  Importantly, HCC1937 pBp and 
UWB1.289 cell lines were used in conjunction with their isogenic, wild-type BRCA1-
reconstituted counterparts.  Clonogenic survival assays confirmed the enhanced 
irradiation sensitivity of the BRCA1 mutant cell line of each isogenic pair relative to the 
BRCA1 wild-type cell line as reported previously (Figure 2.1) (DelloRusso, Welcsh et al. 
2007).  In addition, HCC1937+BRCA1 cells, but not BRCA1 mutant HCC1937 pBp 
cells, showed induction of -H2AX following short-term doxorubicin (dox) treatment 
(Figure 2.2).  We first characterized all cell lines used in this study in terms of baseline 
telomerase activity, BRCA1 protein expression levels, and baseline telomere length, 
factors that might influence sensitivity to telomerase inhibition.  No statistically 
significant differences were observed (by one-way ANOVA) among the cell lines used, 
nor among the isogenic BRCA1 mutant and BRCA1 wild-type cell line pairs, in terms of 
baseline telomerase activity (Figure 2.3). We next performed Western blot analysis using 
a monoclonal BRCA1 antibody that recognizes the full-length BRCA1 gene product 
(MS110) (Scully, Ganesan et al. 1996).  We found that HCC1937 pBp and 
HCC1937+BRCA1 cell lines had relatively low levels of BRCA1, as reported previously 
(S. Elledge, personal communication).  UWB1.289+BRCA1 cell lines had relatively high  
  
34 
 
Table 2.1 BRCA1 mutant and wild-type lines used. 
Cell line  Cancer subtype  BRCA1 status 
MCF7 Luminal breast Wild-type 
MDA.MB.468 Basal A breast (triple negative) Wild-type 
HCC1937 pBp Basal A breast (triple negative) Germline mutation; 5382insC 
HCC1937+BRCA1 Basal A breast (triple negative) Wild-type  
UWB1.289 Papillary serous ovarian carcinoma Germline mutation; 2594delC 
UWB1.289+BRCA1 Papillary serous ovarian carcinoma Wild-type 
MDA.MB.436 Basal B breast Germline mutation; 5396+1 G>A 
SUM149PT Primary inflammatory breast  Somatic mutation; 2288delT 
Six breast cancer cell lines and two ovarian cancer cell lines were obtained from ATCC 
or as described in Materials and Methods.  Four cell lines used contained either a 
germline or a somatic BRCA1 mutation from different regions throughout the full-
length BRCA1 gene.  Two isogenic cell line pairs (HCC1937 pBp/HCC1937+BRCA1 
and UWB1.289/UWB1.289+BRCA1) were included.   
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Figure 2.1. BRCA1 mutant cells show enhanced IR sensitivity. 
Cells were plated in T25 cm
2 
flasks and allowed to attach prior to irradiation at room 
temperature at 0, 1, 2, 3, 4, or 5 Gy.  Following irradiation, cells were incubated at 
37°C and 5% CO2 for 24 hours and then plated in triplicate at low density for 
clonogenic survival. ** p < 0.01, and ***p< 0.001. 
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levels of BRCA1 expression compared to the other cell lines used, with levels appearing 
higher than that of MCF7 cells, a commonly used positive control for BRCA1 protein 
expression (Scully, Ganesan et al. 1996) (Figure 2.3).  UV-irradiated chronic 
myelogenous leukemia K-562 cell lysate (Santa Cruz) was also used as a positive control 
for this assay. Next, we used the TeloTAGGG assay (Roche) to examine baseline 
telomere lengths.  HCC1937 pBp cells had the shortest average telomeres at baseline (3.3 
kb), and UWB1.289+BRCA1 cells had the longest (6.7 kb).  Interestingly, 
HCC1937+BRCA1 cells had a slightly longer average telomere length at baseline (3.7 
kb) compared to HCC1937 pBp cells (3.3 kb), and this result was statistically significant 
(p < 0.05, two-tailed student’s t-test using data from multiple experiments) (Figure 2.4).  
Similarly, UWB1.289+BRCA1 cells had a longer average telomere length at baseline 
(6.7 kb) compared to UWB1.289 cells (5.3 kb), and this result was statistically significant 
(p < 0.01, two-tailed student’s t-test using data from multiple experiments) (Figure 2.4). 
 
BRCA1 Mutant Cells Show Enhanced Sensitivity to GRN163L  
Previous work in our laboratory has demonstrated that HCC1937 pBp cells are 
exquisitely sensitive to GRN163L treatment as measured by the Telomeric Repeat 
Amplification Protocol (TRAP) assay relative to other breast cell lines tested (Hochreiter, 
Xiao et al. 2006).  We hypothesized that this sensitivity might be due to the BRCA1 
mutant status of these cell lines.  To address the importance of BRCA1 in determining 
sensitivity to telomerase inhibition, we first established a dose response after treatment 
for 24 hours with GRN163L in the cell lines in our panel (Figure 2.5, isogenic cell line  
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Figure 2.2. BRCA1 wild-type HCC1937+BRCA1 cells, but not BRCA1 
mutant HCC1937 pBp cells, show induction of of -H2AX following 
doxorubicin treatment. 
Subconfluent cells were plated on 4-well chamber slides and allowed to 
grow for 1-2 days at 37°C and 5% CO2 before 10 minute treatment with 50 
nM doxorubicin (dox).  Doxorubicin treatment was carried out at 37°C and 
5% CO2.  Following treatment, cells were washed in ice cold 1 x HBSS, 
stained for immunofluorescence as described in Materials and Methods, 
and visualized using confocal microscopy. 
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Figure 2.3. BRCA1 mutant and BRCA1 wild-type cell lines show no differences in 
baseline telomerase activity, but express varying levels of BRCA1 protein. 
 (A) Baseline relative telomerase activity (RTA) was measured using the TRAP assay 
as previously described (Hochreiter, Xiao et al. 2006).  Cells were lysed in NP-40 lysis 
buffer (1000 cells/µL).  TSR8 was used as a positive control.  Lysis buffer alone (LB) 
and heat inactivated lysate (Δ) served as negative controls. Products were quantified 
using ImageJ software and presented as the ratio of the telomerase product to the 
internal control (IC) band.  Data was quantified as described in Materials and Methods 
and is presented as the mean and standard deviation of five independent experiments. 
(B) BRCA1 expression levels were determined by loading 50 g protein into 4-15% 
Bis-Tris SDS-PAGE gradient gels (NuPAGE).  Membranes were incubated with 
MS110 antibody for BRCA1 and blotting for a loading control, β-actin, was included.  
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Figure 2.4. BRCA1 mutant and wild-type cell lines exhibit differences in baseline 
telomere length. 
Baseline telomere lengths of cell lines used in this study were determined using the 
TeloTAGGG assay (Roche) according to the manufacturer’s protocol.  
* indicates p < 0.05, and ** indicates p < 0.01, student’s t-test using data from multiple 
experiments. 
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pairs and SUM149PT cells, as examples).  At this timepoint, the UWB1.289 cell line pair 
appears to be more sensitive to telomerase inhibition compared to the HCC1937 cell line 
pair (Figure 2.5).  HCC1937 pBp cells appear to be slightly more sensitive to GRN163L 
treatment at this timepoint compared to HCC1937+BRCA1 cells (EC50 values for 
HCC1937 pBp and HCC1937+BRCA1 cells are 0.147 M and 0.305 M, respectively) 
(Figure 2.5).  Similarly, UWB1.289 cells appear to be slightly more sensitive than 
UWB1.289+BRCA1 cells to inhibitor treatment (EC50 values for UWB1.289 and 
UWB1.289+BRCA1 cells are 0.041 M and 0.104 M, respectively) (Figure 2.5).   
We also tested whether there were differences between late passage (LP = passage 
20 for HCC1937pBp cells and LP= passage 19 for HCC1937+BRCA1 cells) and early 
passage (EP= passage 1 for HCC1937 pBp and HCC1937+BRCA1 cells) HCC1937 pBp 
and HCC1937+BRCA1 cells.  We saw no apparent differences in baseline telomerase 
activity at LP compared to EP for HCC1937+BRCA1 cells, though HCC1937 pBp cells 
appear to show slightly increased telomerase activity at LP compared to EP (Figure 2.6).  
We next examined response to GRN163L in the cell line panel using 12, 24 or 48 hour 
treatment timepoints, and either treatment at plating (simultaneous treatment) or the day 
after plating (next-day treatment). 24 hour next-day treatment showed telomerase 
inhibition ranging from 77% inhibition (MCF7) to 98% inhibition (UWB1.289) with four 
cell lines (MDA.MB.468, UWB1.289, UWB1.289+BRCA1, and SUM149PT) showing 
over 90% inhibition (Figure 2.7A).  No difference was seen between the BRCA1 mutant 
and BRCA1 wild-type cell lines when compared as groups using the 24 hour next-day 
treatment (92+/-6% for BRCA1 mutant versus 85+/-9% inhibition for BRCA1 wild-type 
cell lines, p > 0.05, 2-tailed student’s t-test).  48 hour next-day treatment inhibited  
41 
 
 
  
Figure 2.5. Isogenic cell line pairs and SUM149PT cells exhibit a dose-
dependent response to GRN163L in TRAP assays. 
Cells were plated in 12-well plates and allowed to attach overnight.  The next 
day, media was removed and replaced with fresh media containing GRN163L or 
MM oligonucleotide.  Cells were lysed in NP-40 lysis buffer (1000 cells/µL), and 
processed (TRAP assay) and analyzed as described in Materials and Methods. 
Panel A shows the dose-dependent response to GRN163L in HCC1937 pBp and 
HCC1937+BRCA1 cell lines, and Panel B shows the response to GRN163L in 
UWB1.289 and UWB1.289+BRCA1 cell lines.  Panel C shows the effects of 
GRN163L in SUM149PT cells. 
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Figure 2.6. Effects of passage number on telomerase activity. 
Baseline telomerase activity levels were compared in early passage (p x+1 for HCC1937 pBp 
and p1 for HCC1937+BRCA1) versus late passage (p19 for HCC1937 pBp and p20 for 
HCC1937+BRCA1) cell lines.  Telomerase activity levels are normalized to the positive 
control (MCF7) and presented as percent activity of MCF7 cells (Relative Telomerase 
Activity, or RTA).  
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telomerase activity in all cell lines tested, ranging from 80% inhibition (HCC1937 pBp) 
to approximately 99% inhibition (UWB1.289), with 4 cell lines showing over 90%  
inhibition of telomerase activity (Figure 2.7B).  Using 12-hour simultaneous treatment, 
telomerase inhibition ranged from 74% inhibition (MCF7) to 100% inhibition 
(UWB1.289 and UWB1.289+BRCA1), with 7 cell lines showing over 90% inhibition 
(Figure 2.8A).  24 hour simultaneous treatment yielded similar results, with telomerase 
inhibition ranging from approximately 85% (MCF7) to 100% (SUM149PT), with 6 cell 
lines showing over 90% inhibition (Figure 2.8B).  At all treatment timepoints, regardless 
of whether treatment was simultaneous or next-day, we saw no significant differences in 
telomerase inhibition comparing BRCA1 mutant and BRCA1 wild-type cell lines as 
groups. We observed morphological changes in most of the cell lines tested as early as 12 
hours following simultaneous treatment as previously reported (Goldblatt, Gentry et al. 
2009) (Table 2.2 and Figure 2.9, isogenic cell line pairs as examples).  No notable 
differences were seen in terms of morphology between BRCA1 mutant and BRCA1 wild-
type cell lines at these timepoints.  
To better understand the efficacy of GRN163L in BRCA1 mutant versus BRCA1 
wild-type cell lines, we focused on longer treatment timepoints using the two isogenic 
cell line pairs (HCC1937 and UWB1.289 +/- BRCA1).  Clonogenic survival assays after 
3-week continuous treatment with GRN163L demonstrate the BRCA1 mutant cell line in 
each isogenic pair shows a statistically significant reduction in clonogenic survival 
relative to the BRCA1 wild-type cell line (Figure 2.10).  To verify that the reduction in 
clonogenic survival was due to the telomere shortening effects of GRN163L, we also 
performed clonogenic survival assays at both shorter and longer timepoints.  After 1- 
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Figure 2.7. All cell lines show telomerase inhibition following next-day treatment for 
24 (A) or 48 (B) hr with a clinically relevant concentration of GRN163L. 
Cells were treated the day after plating with 1.7 M GRN163L (+).  Pellets were lysed 
in NP-40 lysis buffer at 1000 cells/µL and used in the TRAP assay as described 
previously (Hochreiter, Xiao et al. 2006; Clark, Rodriguez et al. 2012; Roy, Chun et 
al. 2012). TSR8 and MCF7 cells were used as positive controls, and heat-inactivated 
() or MM-treated cells were used as negative controls. Products were quantified 
using ImageJ software and presented as the ratio of the telomerase product to the 
internal control (IC) band.  Data was quantified as described in Materials and 
Methods, normalized to the untreated telomerase activity level for each cell line, and 
presented as percent inhibition. 
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Figure 2.8. All cell lines show telomerase inhibition following 12 (A) or 24 (B) 
hour simultaneous treatment with a clinically relevant concentration of 
GRN163L. 
Cells were treated at plating with 1.7 M GRN163L (+).  Pellets were lysed in NP-
40 lysis buffer at 1000 cells/µL and used in the TRAP assay as described previously 
(Hochreiter, Xiao et al. 2006). TSR8 and MCF7 cells were used as positive controls, 
and heat-inactivated () or MM-treated cells were used as negative controls. 
Products were quantified using ImageJ software and presented as the ratio of the 
telomerase product to the internal control (IC) band.  Data was quantified as 
described in Materials and Methods, normalized to the untreated telomerase activity 
level for each cell line, and presented as percent inhibition. 
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Table 2.2. Morphologic observations following 12-hour simultaneous treatment.  
 
Cell line Morphologic changes at 12hr post-treatment 
MCF7 Majority attached and in large clumps 
MDA.MB.468 Clumped; few floating 
HCC1937 pBp Slightly rounded; most attached 
HCC1937+BRCA1 Slightly rounded; 60% attached 
UWB1.289 Rounded; 40% attached 
UWB1.289+BRCA1 Rounded; 40% attached 
MDA.MB.436 Majority floating and in large clumps 
SUM149PT Rounded and dark; majority floating 
  
Cells were plated in 12-well dished and treated at plating.  After 12-hour incubation at 
37°C and 5% CO2, cells were imaged and observations were recorded prior to collection 
for TRAP assays.  
47 
 
 
  
 
Figure 2.9. 12-hour Simultaneous treatment with GRN163L induces 
morphologic changes in the majority of cell lines tested.  
Cells were treated at time of plating in 12-well dishes and imaged 12 hours later 
before collection for the TRAP assay.  
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week continuous treatment, we observed a statistically significant reduction in clonogenic 
survival among UWB1.289+BRCA1 cells treated with 3.4 M GRN163L as compared to 
UWB1.289 cells, but this result is difficult to interpret as 3.4 M MM also had more of 
an effect on UWB.1289+BRCA1 cells versus UWB1.289 cells at this timepoint (Figure 
2.11A).  Following 2-week continuous treatment with GRN163L, we saw a statistically 
significant reduction in clonogenic survival at 3.4 and 1.7 M treatment concentrations in 
UWB1.289 versus UWB1.289+BRCA1 cells (Figure 2.11B).  Of note, the fraction of 
UWB1.289 cells still alive at 2 weeks was greater than at 3 weeks.  Furthermore, the 
differences in sensitivity between UWB1.289 and UWB1.289+BRCA1 cells were more 
apparent at 3 weeks versus 2 weeks (p<0.05 vs p<0.001 at 2 weeks and 3 weeks, 
respectively, for 3.4 M GRN163L; p<0.01 vs p<0.001 at 2 weeks and 3 weeks, 
respectively, for 1.7 M GRN163L; and not signficant vs p<0.05 at 2 weeks and 3 weeks, 
respectively, for 0.85 M GRN163L).  By 12 weeks, no differences in response were 
seen between UWB1.289 and UWB1.289+BRCA1 cell lines, but surviving fraction was 
much less than at 1, 2, or 3 weeks of treatment (Figure 2.11C).   
Cumulative population doublings were calculated over longer time periods of 
drug treatment in both isogenic cell line pairs until one or both cell lines of the pair were 
completely depleted.  After approximately 5 weeks of continuous treatment, we saw a 
statistically significant reduction in all treatment groups compared to the MM-treated 
group in HCC1937 pBp cells (p < 0.001 for MM vs 3.4, 1.7, or 0.85 M GRN163L, one-
way ANOVA), and this trend continued until all cells were completely dead at 
approximately 10 weeks (Figure 2.12A).  After 7 weeks of continuous treatment, we saw  
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Figure 2.10. Cells with mutant BRCA1 exhibit decreased clonogenic survival 
following 3-week continuous treatment with GRN163L. 
Following a 3-week continuous treatment with GRN163L or MM, 750-1000 cells were 
seeded on 10 cm
2 
plates and grown undisturbed and untreated for 14-18 days.  Media 
was then aspirated and plates were washed in 1 x HBSS before fixing cells with ice cold 
100 % methanol.  Plates were stained with 0.5% crystal violet in 25% methanol for 10 
minutes at room temperature, rinsed in double-distilled water, and allowed to dry 
overnight.  Colonies consisting of at least 50 cells were scored and data is recorded as 
surviving fraction relative to the corresponding untreated cell line.  * p < 0.05, HCC1937 
pBp vs HCC1937+BRCA1; *** p < 0.001, HCC1937 pBp vs HCC1937+BRCA1; @ p< 
0.01 vs MM, one-way ANOVA. 
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  Figure 2.11. Clonogenic survival capacity progressively decreases with 
increased GRN163L treatment duration. 
Following a 1, 2 or 12-week treatment with GRN163L or MM oligonucleotide, 
cells were seeded at low density on 10 cm
2 
plates and grown undisturbed and 
untreated for 14-18 days.  Media was then aspirated and plates were washed in 1 x 
HBSS before fixing cells with ice cold 100% methanol.  Plates were stained with 
0.5% crystal violet in 25% methanol for ten minutes at room temperature, rinsed in 
double-distilled water, and allowed to dry overnight.  Colonies consisting of at 
least 50 cells were scored and data is recorded as surviving fraction relative to the 
corresponding untreated cell line. *p < 0.05 UWB1.289 vs UWB1.289+BRCA1; 
** p < 0.01 UWB1.289 vs UWB1.289+BRCA1; *** p < 0.001 UWB1.289 vs 
UWB1.289+BRCA1; @ p < 0.05 vs MM, one-way ANOVA. 
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Figure 2.12. GRN163L preferentially induces complete cell death in HCC1937 
pBp BRCA1 mutant cells and abolishes UWB1.289 and UWB1.289+BRCA1 
cell populations at approximately 24 weeks.  
Cells were plated in triplicate at uniform density in 6-well dishes and passaged 
approximately once per week as needed.  Cells were counted at each passage using 
a counter (Beckman Coulter Zm) and replated at uniform density.  Cells were 
continually treated for the duration of the experiment and GRN163L or MM was 
replenished every 3-4 days.  Population doublings were calculated as the log 
[(number of cells collected)/(number of cells initially plated)]/log 2 for each 
passage.  Data is presented as cumulative population doubling level for each 
treatment group.  Arrow denotes approximate time at which all cells were dead.  
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a statistically significant reduction in all treatment groups compared to the MM-treated 
group in HCC1937+BRCA1 cells (p < 0.001 for MM vs 3.4 M GRN163L, and p < 0.05 
for MM vs 1.7, or 0.85 M GRN163L, one-way ANOVA).  Although growth was 
significantly slowed for HCC1937+BRCA1 GRN163L-treated cells, they continued to 
proliferate throughout the duration of the experiment (Figure 2.12B).  UWB1.289 and 
UWB1.289+BRCA1 cell lines took much longer to be affected by telomerase inhibitor 
treatment.  By approximately 10 weeks, we saw a statistically significant reduction in all 
treatment groups compared to the MM-treated group in UWB1.289 and 
UWB1.289+BRCA1 cells (Figure 2.12 C and D).  This trend continued for both cell lines 
until approximately 22 weeks when all cells were depleted.  No differences were 
observed between the UWB1.289 and UWB1.289+BRCA1 cell lines in terms of 
cumulative population doublings after treatment with GRN163L (Figure 2.12 C and D).  
Next, TeloTAGGG assays were performed to access telomere length following drug 
treatment.  This experiment confirmed that telomere shortening occurred over a 3- or 6-
week period following treatment with GRN163L, but not with MM, in both cell line pairs 
tested (Figure 2.13).  UWB1.289 and UWB1.289+BRCA1 cells shortened approximately 
twice as quickly as HCC1937 pBp and HCC1937+BRCA1 cells (Figure 2.14).  
 
GRN163L treatment induces -H2AX expression in BRCA1 mutant cells, but does not 
alter cell cycle dynamics 
Previous work from our laboratory has demonstrated an increase in population 
doubling time with increasing lengths of exposure to GRN163L and an increase in the 
percentage of cells in G2 phase after 9 and 20 days of treatment  
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Figure 2.13. Telomere shortening occurs over a 3 or 6-week period of 
treatment with GRN163L in isogenic cell line pairs. 
Cells were grown untreated or in the presence of GRN163L or mismatch over a 6-
week (A) or 3-week (B) period.  At the specified timepoint, attached and floating 
cells were washed, pelleted, and collected for subsequent use in the TeloTAGGG 
assay to measure telomere restriction fragments (TRFs) as described in Materials 
and Methods.  Average TRF (in kb) is listed at bottom of blots.  
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Figure 2.14. Rate of telomere shortening following 3 or 6-week period of 
treatment with GRN163L in isogenic cell line pairs. 
Rate of telomere shortening was calculated by plotting log[kb] as a function 
of time. 
 
55 
 
Figure 2.15. Simultaneous treatment with GRN163L hinders cell growth and 
increases population doubling time.  
Cells were treated at time of plating and continually treated for the duration of the 
experiment.  GRN163L or MM was replenished every 3-4 days by spiking the media.  
Cells were counted after 7 days using a counter (Beckman Coulter Zm) and 
population doubling time was calculated as the doubling time= experiment 
duration*log(2)/(log[(number of cells collected)-(log[number of cells initially 
plated]).     
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(Gomez-Millan, Goldblatt et al. 2007).  Similarly, we observed decreased cell numbers 
and increased population doubling times as early as 7 days after simultaneous treatment 
(Figure 2.15).  To address the question of whether treatment with GRN163L alters the 
cell cycle dynamics of BRCA1 wild-type versus BRCA1 mutant cell lines, we used flow 
cytometry and propidium idodide staining.  We hypothesized that long-term (1 week or 
greater) treatment with GRN163L would lead to irreparable DNA damage in BRCA1 
mutant cell lines, resulting in changes in cell cycle distribution.  Doxorubicin was 
included as a positive control for these assays.  We examined UWB1.289 and 
UWB1.289+BRCA1 cell lines after 1, 3 and 6 weeks of treatment with GRN163L or 
MM.  No significant differences were observed in cell cycle distribution at these time 
points following treatment with either GRN163L or MM oligonucleotide (Figure 2.16A 
and B, week 6 data).  Treatment with 1M doxorubicin led to a significant decrease in 
the percentage of cells in G1 (p < 0.01, one-way ANOVA) in UWB1.289 and 
UWB1.289+BRCA1 cell lines, and this was coupled with a trend toward an increase in 
the percentage of cells in G2, though this did not reach statistical significance for all 
treatment groups (p > 0.05 for increase in G2 cells in doxorubicin vs GRN163L treated 
groups in both cell lines) (Figure 2.16A and B).  Similarly, we saw no changes in cell 
cycle distribution in HCC1937 pBp and HCC1937+BRCA1 cells after 1, 3, or 6-week 
treatment with GRN163L or MM (data not shown).  
To further investigate the mechanistic effects of GRN163L on BRCA1 mutant 
and wild-type cells, we employed Western blot analysis and immunofluorescence to look 
at DNA repair proteins.  Upon induction of DNA damage, histone H2A becomes  
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Figure 2.16. 6-week continuous GRN163L treatment does not induce cell 
cycle changes in UWB1.289 or UWB1.289+BRCA1 cells.  
Cells were plated at uniform density to permit passage once per week for the 
duration of the experiment.  Media was spiked with GRN163L or MM every 3-
4 days.  At collection, supernatant was collected to be combined with pellet. 
Attached cells were washed in 1xPBS, trypsinized, pelleted, resuspended in 
1xPBS, and incubated in staining buffer containing propidium iodide, RNAse 
A, and NP40 detergent for 30 minutes at 4C.  Flow cytometry analysis was 
performed with FACScan.  1 M of doxorubicin treatment for 48 hours was 
used as a positive control for each cell line.  Experiment was performed in 
triplicate for each treatment group.  ** p < 0.01, 1-way ANOVA. 
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phosphorylated in an ATM/ATR dependent manner (-H2AX), leading to the recruitment 
of homology-directed repair complexes containing BRCA1 (Krum, la Rosa Dalugdugan 
et al. 2010). We used Western blot analysis to assess the effects of GRN163L treatment 
on phosphorylation of -H2AX or protein expression of p21, an inhibitor of G1/S cell 
cycle progression.  As telomere shortening is known to trigger a DNA damage response 
(DDR) and, ultimately, replicative senescence, we reasoned that long-term treatment with 
GRN163L might result in different DDR profiles in BRCA1 wild-type versus mutant 
cells.  After 3 weeks of continuous treatment with GRN163L, BRCA1 mutant 
UWB1.289 cells showed an increase in the phosphorylated form of H2AX.  This 
induction was not seen in UWB1.289+BRCA1 cells until the 6-week timepoint (Figure 
2.17A), indicating either that damage caused by GRN163L is more efficiently repaired in 
the BRCA1 wild-type cells or damage does not occur as robustly at this timepoint in 
UWB1.289+BRCA1 cells.  UV-irradiated K-562 cells were used as a positive control.  
We also used immunofluorescence to visualize -H2AX foci in UWB1.289 and 
UWB1.289+BRCA1 cells following 1-week treatment with GRN163L or MM (Figure 
2.17B).  Using this method, we saw an increase in -H2AX positive cells in UWB1.289 
doxorubicin- and GRN163L-treated groups compared to the BRCA1 wild-type cell line.  
These results agree with those presented in Figure 2.17A and suggest that GRN163L 
treatment induces -H2AX foci as early as one week after treatment and that DNA 
damage persists at 3 and 6 weeks in UWB1.289 cells (Figure 2.17).  After 1 and 3-week 
treatment with GRN163L, HCC1937 pBp cells showed an increase in -H2AX protein 
expression relative to the untreated sample from the same timepoint (Figure 2.18A).  
HCC1937+BRCA1 cells do not show this same induction via Western blot, though some  
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Figure 2.17. UWB1.289 cells show increased -H2AX expression compared to 
UWB1.289+BRCA1 cells following 1-week (immunofluorescence) or 3-week (Western 
blot) continuous treatment with GRN163L. 
(A) Western blot analysis.  Cells were continuously grown untreated (UT) or treated for 1, 
3, or 6 weeks with GRN163L (+ denotes 1.7 μM GRN163L) or 1.7 μM Mismatch (MM) 
oligonucleotide.  At collection, cells were washed in 1 x PBS, trypsinized, and pelleted.  
Supernatant was collected and combined with attached cells in the pellet for Western blot 
analysis as described in Materials and Methods.  (B) Immunofluorescence.  Cells were 
plated on 4-well chamber slides and grown in the presence of GRN163L or MM for 7 
days.  Media was removed every 3 days and replaced with fresh media or fresh media 
containing the appropriate oligonucleotide.  On day 7, media was removed and slides were 
washed in ice cold 1 x PBS and fixed for 15 min. at room temperature in a 3:1 mixture of 
MeOH:acetic acid.  Slides were blocked in 5% BSA in PBS for 1 hr at room temperature, 
and incubated with -H2AX antibody (Millipore) as described in Materials and Methods. 
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Figure 2.18. GRN163L induces -H2AX expression in HCC1937 pBp and 
HCC1937+BRCA1 cells after 1- or 3-week treatment. 
(A) Western blot analysis.  Cells were continuously grown untreated (UT) or treated for 
1 or 3 weeks with GRN163L (+ denotes 1.7 μM GRN163L) or 1.7 μM Mismatch (MM) 
oligonucleotide.  At collection, cells were washed in 1 x PBS, trypsinized, and pelleted.  
Supernatant was collected and combined with attached cells in the pellet for Western 
blot analysis as described in Materials and Methods.  (B) Immunofluorescence.  Cells 
were plated on 4-well chamber slides and grown in the presence of GRN163L or MM 
for 21 days.  Media was removed every 3 days and replaced with fresh media or fresh 
media containing the appropriate oligonucleotide.  On day 7, media was removed and 
slides were washed in ice cold 1 x PBS and fixed for 15 min at room temperature in a 
3:1 mixture of MeOH:acetic acid.  Slides were blocked in 5% BSA in PBS for 1 hr at 
room temperature, and stained for immunofluorescence as described in Materials and 
Methods. 
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-H2AX foci are evident using immunofluoresnce after 3-week treatment with GRN163L 
(Figure 2.18A and B).    
 
GRN163L pretreatment or concurrent treatment synergizes with DNA damaging agents 
Reduced telomerase expression has been reported to compromise DNA repair in 
primary fibroblasts (Masutomi, Possemato et al. 2005).  Given the ability of GRN163L to  
inhibit telomerase and induce DNA damage, we next investigated whether concurrent 
treatment with GRN163L might sensitize cells to DNA damaging agents commonly used 
in the treatment of breast and ovarian cancer.  When UWB1.289 and 
UWB1.289+BRCA1 ovarian cancer cell lines were treated with GRN163L and cisplatin 
simultaneously, this combination was found to be antagonistic at all concentrations tested 
(data not shown).  Next, we pretreated UWB1.289 and UWB1.289+BRCA1 cells for 6 
weeks with 0.85 M GRN163L to induce telomere shortening (Figure 2.13B, data shows 
shortening up to 3 weeks).  After a 6-week treatment, GRN163L was removed and cells 
were treated with various concentrations of cisplatin.  The effects of GRN163L 
pretreatment augmented the action of cisplatin in both HCC1937 pBp and 
HCC1937+BRCA1 cell lines (Figure 2.19A).  The results of 0.85 M GRN163L 
treatment followed by cisplatin treatment were compared to untreated cells and to cells 
treated with 0.85 M GRN163L for the duration of the experiment.  Next, we examined 
the combination effects of GRN163L and topoisomerase II inhibitor doxorubicin in 
breast cancer cell lines HCC1937 pBp and HCC1937+BRCA1.  The combination of 
GRN163L and doxorubicin added simultaneously was synergistic at the majority of 
concentration combinations tested in both cell lines (Figure 2.19B).   
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Figure 2.19. GRN163L pretreatment augments the action of cisplatin (A) and 
concurrent GRN163L treatment synergizes with doxorubicin (B).  
Cells were grown in 96-well plates in the presence of fresh media, doxorubicin, 
GRN163L, a combination of doxorubicin and GRN163L, or cisplatin.  After 72 hr, 
media was removed and cells were fixed in 100% methanol and stained with 
methylene blue.  The methylene blue colorimetric assay measures proliferation based 
on optical density (Oliver, Harrison et al. 1989).  Synergism was defined as a 
combination index (CI) value < 1 and was determined using Calcusyn software and 
the Chou-Talalay method (Chou and Talalay 1984). 
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Discussion 
In summary, our work demonstrates differences in response to GRN163L 
between BRCA1 mutant and BRCA1 wild-type cell lines. Importantly, these differences 
only became apparent upon longer treatment timepoints at which the telomere-shortening 
effects of GRN163L were evident.  At all treatment timepoints using the TRAP 
telomerase activity assay, regardless of whether treatment was simultaneous or next-day, 
we saw no significant differences in telomerase inhibition comparing BRCA1 mutant and 
BRCA1 wild-type cell lines as groups.  This finding is not entirely surprising, 
considering we found no differences among these cells in terms of baseline telomerase 
activity (Figure 2.3A).  Additionally, no timepoint tested in the TRAP assay was 
sufficient to see effects dependent upon baseline telomere length and the telomere-
shortening effects of GRN163L.  The differences in sensitivity were not due to 
differences in telomerase activity, as all cell lines were found to have the same activity 
levels at baseline.  This finding contradicts a previous report detailing lower levels of 
telomerase activity following exogenous BRCA1 overexpression (Xiong, Fan et al. 
2003).  This discrepancy could be due to differences in methodology (Xiong et al. use of 
exogenous BRCA1 stable and transient transfection vs our use of established cell lines 
with endogenous BRCA1 or BRCA1 stably transduced).  
The increased sensitivity of HCC1937 pBp and UWB1.289 cells to GRN163L 
relative to their BRCA1 wild-type counterparts could be due to differences in baseline 
telomere length, as demonstrated by the TeloTAGGG assay (Figure 2.4).  The 
TeloTAGGG assay revealed a difference in baseline telomere length between HCC1937 
pBp and HCC1937+BRCA1 cell lines and between UWB1.289 and UWB1.289+BRCA1 
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cell lines, with the BRCA1 mutant cell line of each isogenic pair having shorter 
telomeres.  As predicted based on this result, HCC1937 pBp and UWB1.289 cells are 
more sensitive to GRN163L compared to their wild-type BRCA1 counterparts after 3-
week treatment in clonogenic survival assays (Figure 2.10).  This difference in sensitivity 
is evident in longer treatments with the HCC1937 pBp cell line (see population doubling 
experiment, Figure 2.12A and B), but not with the UWB1.289 cell line (Figure 2.12 C 
and D).  Interestingly, we do, however, see that both UWB cell lines (which had among 
the longest telomeres at baseline) continue to grow and proliferate longer in the presence 
of drug relative to the HCC cell lines (which had among the shortest telomeres at 
baseline) (Figure 2.4 and Figure 2.12).  This result could be a limitation of the assay as 
cells must be continually cultured and passaged in the presence of drug for several weeks 
and those cells less affected are most likely to be those collected after this time period. 
Given the relatively short baseline telomere lengths of HCC1937 pBp and 
HCC1937+BRCA1 cell lines, we predicted they would be more sensitive to telomerase 
inhibition compared to cell lines with longer telomeres at baseline.  In fact, we see these 
cell lines begin to die off much earlier than the UWB1.289/UWB1.289+BRCA1 cell line 
pair in population doubling studies (Figure 2.12).  This finding correlates with both of the 
UWB cell lines having relatively longer average telomere lengths at baseline compared to 
most of the other cell lines in the panel (Figure 2.4).     
In long-term population doubling studies, we observed HCC1937 pBp cells die 
off earlier than HCC1937+BRCA1 cells, and this result could be predicted based on the 
TeloTAGGG assay, as HCC1937 pBp cells had a slight, but statisitically significant, 
reduction in baseline telomere length compared to HCC1937+BRCA1 cells  (Figure 2.4).  
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We cannot, however, rule out the possibility of a few very short telomeres in the 
HCC1937 pBp cell line, which cannot be detected using the resolution of the 
TeloTAGGG assay.  As predicted by the shortest telomere hypothesis, the shortest one or 
two telomeres will predict sensitivity to telomerase inhibition, regardless of the average 
telomere length of a cell population (Harley 2008).  Measuring only the shortest 
telomeres in a population has its challenges, and, even when detected, it is very difficult 
to establish a cause and effect relationship between the shortest telomeres and inhibitor 
response. 
We demonstrate the effects we see following GRN163L treatment are due to the 
telomere shortening properties of the drug, with telomere shortening occurring over a 3- 
or 6- week period after treatment with GRN163L, but not MM oligonucleotide (Figure 
2.13).  The differences in sensitivity seen between BRCA1 mutant and BRCA1 wild-type 
cell lines was likely not due to changes in cell cycle dynamics, as we saw no significant 
differences in cell cycle distribution following 6-week continuous treatment with 
GRN163L (Figures 2.16 and 2.17).  Though we anticipated a change in cell cycle 
distribution after long-term treatment with GRN163L, we may not have seen this due to a 
number of factors. For instance, lack of a normal DNA damage response in BRCA1 
mutant cells suggests they will be less likely to halt the cell cycle due to DNA damage 
and will continue proliferating in the presence of damage (Deng 2006).  Furthermore, 
UWB1.289 and UWB1.289+BRCA1 cells harbor an acquired somatic mutation in p53 
(DelloRusso, Welcsh et al. 2007), and recent work suggests cell cycle arrest following 
prolonged mitotic arrest and telomere deprotection is p53-dependent (Hayashi, Cesare et 
al. 2012).  In addition, based on the population doubling level results, a 6-week treatment 
66 
 
may not be sufficient to see the cell cycle effects of GRN163L, as HCC1937 pBp cells, 
the first to die off, do not begin to do so until approximately 7 weeks of treatment (Figure 
2.12).  Our result may be due to not being able to see cell cycle changes until the 
population ceases to grow after protracted GRN163L treatment. 
Differences in sensitivity to GRN163L may be due to differences in the DNA damage 
response between UWB1.289 and UWB1.289+BRCA1 cell lines, with persistent -H2AX 
foci in UWB1.289 cells indicating an inability to repair DNA damage following treatment 
with GRN163L.  These results led us to investigate whether GRN163L works synergistically 
with DNA damaging chemotherapeutics, such as cisplatin and doxorubicin.  We found the 
combination of GRN163L and cisplatin used concurrently were antagonistic.  Six-week 
pretreatment and removal of GRN163L, following by addition of cisplatin for 72 hours, was 
synergistic at the majority of concentration combinations tested for both UWB1.289 and 
UWB1.289+BRCA1 cell lines.  This result suggests the telomere-shortening effects of 
GRN163L, rather than the chemistry of the oligonucleotide itself, impart enhanced sensitivity 
to cisplatin.  The combination of GRN163L and doxorubicin added simultaneously was 
synergistic at the majority of concentration combinations tested in HCC1937 pBp and 
HCC1937+BRCA1 cell lines.  This result is in agreement with a report that GRN163L 
potentiates the effects of G2-specific topoisomerase II inhibitor etoposide.  The combination 
effect with GRN163L is thought to be due to the cell-cycle specific action of etoposide 
(Tamakawa, Fleisig et al. 2010). 
We also cannot rule out the possibility that some mutations in BRCA1 confer 
more sensitivity to GRN163L than others.  From our results, it is difficult to discern 
whether this is the case, as such an assessment must also take into account both baseline 
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telomere length and population doubling time of cell lines.  If loss of heterozygosity 
(LOH) in BRCA1 mutant carriers occurs before reactivation of telomerase in cancer 
development, these patients may benefit from preventative treatment with a telomerase 
inhibitor.  It is also possible that telomerase activity levels are higher at baseline higher in 
BRCA1 mutation carriers because they lack one functional copy of BRCA1.  As such, 
BRCA1 mutation carriers may benefit from telomerase inhibitor treatment to attenuate 
telomerase expression levels and stave off cancer development.  In conclusion, this work 
highlights the multiple factors that must be taken into account in predicting cancer cell 
sensitivity to telomerase inhibition, including BRCA1 status, and lays a foundation for 
further investigation into the mechanism of action of GRN163L in BRCA1 mutant and 
wild-type cells.   
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Materials and Methods 
 
1. Cell culture  
a. HCC1937 pBp (pBabepuro, empty vector) and HCC1937+BRCA1  
HCC1937 pBp and HCC1937+BRCA1 cells were kind gifts from Dr. Stephen Elledge.  
HCC1937 pBp and HCC1937+BRCA1 cells were maintained in DMEM 10% fetal 
bovine serum (FBS).  HCC1937+BRCA1 cells were periodically treated with 1 µg/mL 
puromycin to select for maintenance of the vector containing wild-type BRCA1.  Cells 
were grown at 37°C and 5% CO2 and split every 4-7 days.  Media was replenished 2-3 
times per week and cells were routinely tested for mycoplasma contamination (Sigma). 
b. UWB1.289 and UWB1.289+BRCA1 
UWB1.289 and UWB1.289+BRCA1 cells were purchased from the American Type 
Culture Collection (ATCC, Rockville, Md, USA) and maintained in RPMI:MEGM at a 
ratio of 1:1 supplemented with 3% FBS and SingleQuot additives (Clonetics).  
UWB1.289+BRCA1 cells were grown under G-418 (200 µg/mL) selection for 
maintenance of the vector containing BRCA1.  G-418 was removed from media when 
UWB1.289+BRCA1 cells were treated with GRN163L or mismatch oligonucleotide.  
During long-term treatments (greater than 3 weeks), UWB1.289+BRCA1 cells were 
periodically selected with G-418 at splitting.  Cells were grown at 37°C and 5% CO2 and 
split every 4-7 days.  Media was replenished 2-3 times per week and cells were routinely 
tested for mycoplasma contamination (Sigma). 
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c. MCF7 
MCF7 cells (ATCC) were maintained in DMEM 10% FBS.  Cells were grown at 37°C 
and 5% CO2 and split every 3-4 days.  Cells were routinely checked for mycoplasma 
contamination (Sigma). 
d. MDA.MB.436 
MDA.MB.436 cells (ATCC) were maintained in MEM 10% FBS, 1 mM sodium 
pyruvate, 1 M Hepes, and 2 x MEM vitamins.  Cells were grown at 37°C and 5% CO2 
and split every 3-4 days.  Cells were routinely checked for mycoplasma contamination 
(Sigma). 
e. MDA.MB.468 
MDA.MB.468 cells (ATCC) were cultured in DMEM 10% FBS and maintained at 37°C 
and 5% CO2.  Cells were split every 3-4 days and routinely tested for mycoplasma 
contamination (Sigma). 
f. SUM149PT 
SUM149PT cells were a kind gift from Dr. George Sledge (Stanford University, formerly 
of Indiana University School of Medicine).  SUM149PT cells were maintained in Ham’s 
F-12, 5% cosmic calf serum (CCS), 5 µg/mL insulin, and 1 µg/mL hydrocortisone. Cells 
were grown at 37°C and 5% CO2 and split every 3-4 days.  Cells were routinely checked 
for mycoplasma contamination (Sigma). 
 
2. Oligonucleotides  
The lipid-modified N3′→P5′ thiophosphoramidate oligonucleotide GRN163L (5′-Palm-
TAGGGTTAGACAA-NH2-3′) has a sequence complementary to the hTR template 
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region (also known as imetelstat).  Either a mismatch (30S GRN140833, 5’-Palm-
TAGGTGTAAGCAA-3’, mismatch sequences underlined) or sense oligonucleotide 
(GRN140832, 5’-Palm-ATCCCAATCTGTT-3’) was used as a negative control for these 
studies (both are referred to as MM in the text) (Herbert, Gellert et al. 2005).  All 
oligonucleotides used in this study were provided by Geron Corporation. 
 
3. Treatment with GRN163L 
Cells were allowed to attach overnight prior to treatment with GRN163L or MM.  Where 
multiple treatment concentrations were used, media was removed the day after plating 
and replaced with a 1:2 serial dilution series of GRN163L or MM.  After 24 or 48 hours, 
1.0 x 10
5 
cells were collected for the TRAP (Telomeric Repeat Amplification Protocol) 
assay.  For clonogenic survival assays, cells were treated with GRN163L or MM the day 
after plating.  Drug was refreshed by spiking the media or by replacing the media with 
fresh media containing GRN163L or MM every 3-4 days.  Where multiple treatment 
concentrations were used, a 1:2 serial dilution series of GRN163L or MM control was 
prepared (Figure 2.20).  Alternatively, cells were treated at plating (simultaneous 
treatment).  After 12 or 24 hours simultaneous treatment, 1.0 x 10
5 
cells were collected 
for the TRAP assay.  For simultaneous treatment clonogenic survival assays, cells were 
treated with GRN163L or MM at plating and drug was refreshed by spiking the media 
every 3-4 days for a period of three weeks prior to plating at low density (Figure 2.21). 
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Figure 2.20. Next-day treatment set-up. 
For next-day treatment, cells were plated and allowed to attach overnight.  The next 
morning, media was removed and replaced with fresh media, or fresh media containing 
GRN163L or MM oligonucleotide.  For long-term studies, cells were passaged once per 
week, and media or drug was replenished every 3-4 days.   
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Figure 2.21. Simultaneous treatment set-up. 
For simultaneous treatment, cells were untreated or treated with GRN163L 
or MM oligonucleotide at time of plating.  Fresh media or drug was added 
on Day 4 when cells were used for clonogenic survival assays following 1 
week simultaneous treatment. 
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4. Telomerase activity by the Telomeric Repeat Amplification Protocol (TRAP) 
TRAP assays were performed as previously described (Hochreiter, Xiao et al. 2006).  
Briefly, cells were lysed in NP-40 lysis buffer (1000 cells/L) and telomerase products 
were extended via 30-minute incubation with a Cy5 fluorescently labeled telomerase  
template primer.  Extended products were amplified using PCR, and products were run 
on 10% nondenaturing acrylamide gels.  Gels were visualized using a PhosphorImager 
and ImageQuant software.  Products were quantified using ImageJ software and 
presented as the ratio of the telomerase product to the internal control band.  
 
5. TeloTAGGG telomere measurement assays 
Cells were grown untreated or in the presence of GRN163L or MM over a 3- or 6-week 
period.  After each timepoint as indicated in the Results section, attached and floating 
cells were washed, pelleted, and used for DNA extraction per the manufacturer guidelines 
(Qiagen, Valencia, CA).  DNA was digested using Rsa1/Hinf1 to leave telomeric DNA.  
Digested fragments were separated on a 0.8% agarose gel, blotted to a nylon membrane 
(Roche) using capillary transfer and 20 x SSC (Invitrogen) buffer.  Following overnight 
transfer, DNA was UV-crosslinked to the membrane (Spectrolinker) and a non-
radioactive DIG-labeled telomeric probe was hybridized to the membrane.  The 
membrane was visualized using chemiluminescence.  Mean TRF lengths were calculated 
using ImageJ software (Herbert, Hochreiter et al. 2006).  Briefly, a grid of 30 boxes was 
positioned over each lane, and the signal intensity and size (kb) corresponding to each 
box was determined (Figure 2.22).  
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Figure 2.22. Measurement of telomere length using TeloRun. 
Mean telomere lengths and telomere length distributions were calculated using the 
TeloRun program.  Briefly, a grid of 30 boxes was drawn and superimposed on the 
molecular weight marker lane.  The grid was then copied and laid over each sample lane 
of the gel (left).  Relative to the where the molecular weight marker was in the grid, a 
density distribution plot correlating to kilobase lengths was constructed (right) for each 
sample when the grid was overlaid on sample lanes.  The x-axis of the distribution plot 
denotes the number of the box on the grid (starting with box 1 at the top), and the y-axis 
denotes density.  The peak of the density distribution plot correlates to the average 
telomere length for each sample.  A line was drawn between markers from opposing 
sides of each gel to ensure the grid was properly aligned for each sample lane in relation 
to the alignment of the grid on the molecular weight marker (adapted from TeloRun, 
http://www4.utsouthwestern.edu/cellbio/shay-wright/research/sw_lab_methods.htm). 
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Average telomere length was visualized by drawing a line across the lanes as described 
previously (Hochreiter, Xiao et al. 2006). 
 
6. Cell counting for long-term treatment population doubling study 
Cells were plated at uniform density in 6-well dishes and passaged approximately once 
per week if needed.  Cells were counted at each passage using a counter (Beckman  
Coulter Zm) and replated at uniform density and continually treated for the duration of 
the experiment.  Drug was replenished every 3-4 days by spiking the media or replacing 
the media with fresh media containing GRN163L or MM.  Population doublings were 
calculated as the log[(the number of cells collected)/(number of cells initially 
plated)]/log2 for each passage.  Data is presented as cumulative population doubling level 
for each treatment group. 
 
7. Clonogenic survival  
Following a 1-, 2-, 3-, or 12-week treatment with GRN163L or MM oligonucleotide, 
750-1000 cells were seeded on 10 cm
2 
plates and grown undisturbed and untreated for 
14-18 days.  Media was then aspirated and plates were washed with 1 x HBSS before 
fixing with ice cold 100% methanol.  Plates were stained with 0.5% crystal violet in 25% 
methanol for 10 minutes at room temperature, rinsed in double-distilled water, and 
allowed to dry overnight.  Colonies consisting of at least 50 cells were scored and 
recorded as surviving fraction versus untreated. 
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8. Methylene blue proliferation assay for combination studies 
Cells were grown in 96 well plates in replicates of eight in the presence of fresh media 
and varying concentrations of: cisplatin, GRN163L, doxorubicin, or a combination of 
doxorubicin and GRN163L (or cisplatin and 6-wk GRN163L-treated cells).  After 72 
hours, media was removed and cells were fixed in 100% methanol for 15 minutes at room 
temperature and stained with 0.05% methylene blue for 15 minutes with rocking at room 
temperature.  Plates were rinsed with diH20 and allowed to dry overnight.  The next 
morning, plates were de-stained with 100 L/well of 0.5 M HCl with shaking at room 
temperature.  Optical density readings were collected at 610 nm using an absorbent plate 
reader and recorded as fraction affected relative to the untreated group.  Synergism was 
defined as a combination index (CI) value <1 was determined using Calcusyn software 
and the Chou-Talalay method (Chou and Talalay 1984). 
 
9. Western blot analysis 
Cells were treated continuously for three weeks with GRN163L or MM.  At collection, 
cells were washed in 1xPBS, trypsinized, pelleted, and snap frozen until lysis in RIPA 
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 37 mM ß-glycerol phosphate, 47 mM 
NaF, 1% NP40, 0.1% SDS, 0.5% Na deoxycholate, 10% glycerol, and protease inhibitor 
cocktail).  Supernatant was collected and combined with attached cells in the pellet. 25 or 
50 g protein was loaded into 4-15% Bis-Tris SDS-PAGE (denaturing, reduced) gradient 
gels (NuPAGE) and run from 50 min-120 min (BRCA1) at 200 V.  Protein was 
transferred to PVDF membrane at 10 V overnight at 4°C. Membranes were blocked 
overnight at 4°C in 5% BSA or 5% milk in PBS-T.  BRCA1 MS110 antibody 
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(Calbiochem) was used at 1:200.  -H2AX (Millipore) antibody was used at 1:1000 in 5% 
BSA in PBS-T.  P-95 antibody (Signalway) was used at1:5000 in 5% BSA in PBS-T.  β-
actin (Sigma) was included as a loading control and was used at 1:5000. P21 antibody 
(Cell Signaling) was used at 1:2000 in 5% milk in PBS-T.  
 
10. Flow cytometry 
Cells were plated at uniform density to permit passage once per week for the duration of 
the experiment.  Media was spiked with GRN163L or MM every 3-4 days.  At the 
indicated timepoint, supernatant was collected and attached cells were collected as well 
by trypsinization.  Cells were pelleted, resuspended in 1 x PBS and incubated in staining 
buffer (1 x PBS, 50 g/mL propidium iodide, 200 ng/mL RNAse A, and 0.3% NP40) for 
30 minutes at 4°C.  Flow cytometry analysis was performed with FACScan (Becton 
Dickinson Biosciences).  1M of doxorubicin treatment for 48 hours was used as a 
positive control for each cell line.  The experiment was performed in triplicate for each 
treatment group. 
 
11. Immunofluorescence  
Cells were plated on 4-well chamber slides and allowed to grow for 2-3 days before 
subconfluent cells were fixed with methanol and acetic acid at a ratio of 3:1 for 15 min at 
room temperature.  No additional permeabilization step was used.  Slides were washed 
and 3 times in 1 x PBS and blocked in 5% BSA for 1 hour at room temperature.  Primary 
antibody for γ-H2AX (Millipore) was used at 1 g/mL in 5% BSA overnight at 4°C.  
Secondary antibody rhodamine red-X (Molecular Probes) was used at 1:1000 in 5% BSA 
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in 1 x PBS.  Slides were mounted with VECTASHIELD mounting medium with DAPI 
(Vector Laboratories) and fluorescent images were captured using a Leica DM5000B 
microscope and SPOT software (Diagnostic Instruments).  Fifty cells were counted per 
treatment group, and the number of cells positive for at least 1 γ-H2AX focus was 
recorded as a percentage of the total cells counted. 
 
12. Statistical analyses 
Graph Pad Prism 4.0 software was used to conduct one-way ANOVA analysis, in which 
each treatment group was compared to all other treatment groups to determine statistical 
significance (where p < 0.05 was considered statistically significant).  Calcusyn software 
(Biosoft) was used to determine combination effects via the Chou and Talalay method.  A 
combination index (CI) value of < 1.0 indicates a synergistic interaction, a CI of 1.0 
shows an additive effect, and a CI > 1.0 denotes an antagonistic effect (Chou and Talalay 
1984).    
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CHAPTER THREE 
ANALYSIS OF TELOMERE LENGTH DISTRIBUTION AND TELOMERE-
ASSOCIATED GENE EXPRESSION PROFILES IN BRCA INDIVIDUALS 
 
Abstract 
Telomere dysfunction, telomere shortening, and deregulation of shelterin 
components have been linked to a variety of age-related ailments, including cancer.  
Recent evidence suggests the BRCA1 tumor suppressor has a role in telomere 
maintenance, and genetic anticipation coupled with telomere shortening has been 
reported in BRCA1 carriers.  The direct effects of BRCA1 haploinsufficiency on 
telomere maintenance and predisposition to cancer development are largely unknown.   
To address these questions, we utilized RNA and DNA from peripheral blood leukocytes 
to assess telomere gene expression profiles and telomere length distribution in BRCA1 
carriers, BRCA2 carriers, and sporadic and familial breast cancer individuals.  We found 
overexpression of telomere-associated and telomere-proximal genes, including genes 
involved in negative regulation of telomere length, in BRCA1 carriers compared to all 
other cancer types.  This study provides a potential mechanism by which telomere 
dysfunction may occur in BRCA carriers prior to loss of the remaining wild-type allele 
and links BRCA1 haploinsufficiency to changes in telomere length and gene expression.  
In addition, this work further distinguishes BRCA1 cancers from BRCA2 and other 
familial cancers and provides evidence that therapeutic targets aimed at telomerase or 
shelterin interactions may benefit this patient population. 
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Introduction 
Multiple studies of cells from BRCA mutation carriers suggest “one-hit” effects 
occur even before loss of the remaining wild-type allele and precede development of 
disease. For instance, cultured epithelial cells from heterozygous carriers of BRCA1 or 
BRCA2 mutations exhibit genomic instability characterized by gene copy number loss 
and decreased homology-directed repair capacity in in vitro assays (Konishi, Mohseni et 
al. 2011).  Other work suggests this instability may be due to deregulation of genes 
involved in the G2/M cell cycle transition and DNA damage response in BRCA1 
heterozygous mutant cells, while BRCA2 heterozygous mutant cells show deregulation 
of genes involved in the G1/S cell cycle checkpoint.  Interestingly, BRCA1, but not 
BRCA2, heterozygous epithelial cultured cells show upregulation of the secretoglobin 
family of genes and expression profiles similar to those seen in stem and progenitor cells 
(Bellacosa, Godwin et al. 2010).  This finding corroborates with work suggesting a role 
for BRCA1 in regulating stemness and differentiation in breast progenitor cells (Liu, 
Ginestier et al. 2008).  Expression profiles of heterozygous BRCA1 mutant cells also 
show similarities to hereditary breast cancers from BRCA1 individuals.  A separate study 
demonstrated increased proliferation and clonogenic capacity, coupled with EGFR 
activation, in primary mammary epithelial cells from BRCA1 mutation carriers (Burga, 
Tung et al. 2009).  Telomere dysfunction has been hypothesized to account for the 
unstable phenotype of cells derived from heterozygous BRCA mutation carriers, and may 
explain their predisposition to cancer development. 
Telomere dysfunction and telomere shortening have been linked to a variety of 
human age-related ailments, including cardiovascular disease (Fyhrquist and Saijonmaa 
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2012), neurodegenerative disease (Panossian, Porter et al. 2003; Guan, Maeda et al. 
2008), chronic inflammatory disease (Andrews, Fujii et al. 2010), and cancer (Armanios 
and Blackburn 2012).  An analysis of case control studies revealed an association 
between short telomeres and elevated risk for cancers of the bladder, head and neck, lung 
and kidney (Wu, Amos et al. 2003).  Genetic anticipation, or earlier age of onset and 
sometimes severity of disease in successive generations, has been attributed to telomere 
shortening in familial cancer syndromes such as Li-Fraumeni and dyskeratosis congenita 
(Tabori et al 2007, Vulliamy et al 2004).  A recent report described an association 
between genetic anticipation and shortened telomeres in hereditary breast cancers 
(BRCA1, BRCA2, and BRCAX), but not in sporadic breast cancers (Delgado et al 2011).  
A similar study of ovarian cancer found significantly shorter telomeres in peripheral 
blood leukocytes in both sporadic and hereditary cases compared to healthy controls; 
thus, the roles of BRCA1 and BRCA2 in telomere shortening in ovarian cancer are 
unclear (Martinez-Delgado, Yanowsky et al. 2012).  A separate report found no 
differences in telomere length of peripheral blood leukocytes between ovarian cancer 
cases and controls, but suggests single nucleotide polymorphisms (SNPs) in the TERT 
gene are associated with elevated ovarian cancer risk (Terry, Tworoger et al. 2012).  In 
addition, lifestyle factors such as stress, diet, weight, and cigarette smoking are correlated 
with telomere length, but likely also have roles in development of disease though 
additional mechanisms (Epel, Blackburn et al. 2004; Valdes, Andrew et al. 2005; Paul 
2011). 
Such studies are largely association-based, and the factors driving telomere 
shortening and dysfunction and their contributions to disease development remain largely 
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unknown.  Efforts to shed light on the mechanisms driving telomere dysfunction in 
cancer, though limited, have offered helpful clues.  For instance, elevated levels of TRF2 
have been reported in advanced breast cancers, and expression levels correlate with 
telomere shortening (Diehl, Idowu et al. 2011).  Similarly, Hu et al. found elevated 
expression of TRF1, TRF2, TERT, and Ku70 in precancerous lesions, gastric cancer 
tissues, and gastric cancer with lymph node metastasis compared to normal gastric tissue.  
Importantly, levels of these proteins were significantly higher in gastric cancers with and 
without metastasis compared to precancerous lesions, and mean telomere length was 
inversely correlated with levels of TRF1, TRF2, TERT, and Ku70.  Furthermore, BRCA1 
was localized in the nucleus in normal gastric mucosa, but found primarily in the 
cytoplasm in precancerous lesions and gastric cancer, and cytoplastmic export of BRCA1 
correlated with decreased telomere length (Hu, Zhang et al. 2010).  In another recent 
study, Yanowsky and colleagues looked for sequence variation in telomere-associated 
genes in BRCA negative individuals with short telomeres and a family history of breast 
cancer (Yanowsky, Barroso et al. 2012).  This study yielded noncoding variants, but no 
pathogenic role for the variants was found using functional predication analysis and 
control population studies.  Evidence from Lou and colleagues suggests that telomere 
length can regulate gene expression (Lou, Wei et al. 2009).  Namely, telomere 
shortening, but not replicative senescence or DNA damage signaling per se, led to 
upregulation of interferon-stimulated gene 15 (ISG15) prior to a DNA damage response 
triggered by telomere shortening.  The increase in ISG15 expression was confirmed in 
human skin samples with increased age.  This work provides insight into a possible 
mechanism for maintaining cellular homeostasis and reveals clues to a potential 
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mechanism by which accelerated telomere shortening could lead to an increase in 
inflammation-related gene expression and cancer development (Lou, Wei et al. 2009).  
The objective of this study was to determine average telomere length and length 
distribution in peripheral blood leukocytes of BRCA mutation carriers compared to age-
matched controls and sporadic and familial breast cancers.  In addition, we aimed to 
identify factors that contribute to telomere dysfunction and genetic anticipation 
associated with cancer, particularly in BRCA individuals, and to correlate gene 
expression changes with telomere lengths.  To this end, we assessed expression of 
telomere-associated genes and of telomere-proximal genes (genes within 1000 kb of the 
telomere) using the gene list from GEO Datasets GSE6799, previously published by Lou 
et al.(Lou, Wei et al. 2009).  This work sheds light on the role of BRCA1 in telomere 
maintenance and on the mechanism of sensitivity of BRCA1 mutant cells to telomerase 
inhibition.     
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Results 
Characteristics of patient samples and normal controls 
All BRCA, sporadic, and familial blood samples were a generous gift from Dr. 
Lida Mina (IUSM).  We obtained peripheral blood samples from ten BRCA1 carrier 
individuals, ten BRCA2 carrier individuals, nine individuals with familial breast cancer 
(individuals with no identified BRCA mutation but a family history of breast cancer), and 
eleven individuals with sporadic breast cancer.  We also obtained peripheral blood from 
ten healthy control individuals to correct for age-related telomere shortening in telomere 
length assays.  Individuals with sporadic breast cancer ranged in age from 36-70 years 
(mean age 52.09 +/- 12.84 years) (Table 3.1).  The mean age at diagnosis of sporadic 
individuals was 38.45 +/- 10.61 years.  4/10 sporadic patients had lymph node 
involvement, and the majority (8/11) had ER+ disease (Table 3.2). 
The mean age among BRCA1 carrier individuals was 46.6 +/- 11.64 years, and 
this did not differ significantly from the mean age of sporadic individuals (Tables 3.1 and 
3.3, p > 0.05, one-way ANOVA).  Of the ten BRCA1 carriers, five had developed breast 
cancer at the time of sampling, with a mean age at diagnosis of 39 +/- 4.2 years (Table 
3.4).  Though a trend was seen toward earlier development of breast cancer in BRCA1 
carriers, the age of onset in BRCA1 individuals who developed cancer was not 
significantly different as compared to age of onset of sporadic breast cancer among our 
sample population (p > 0.05, one-way ANOVA).  Of those BRCA1 carriers who 
developed cancer, none had lymph node involvement, and 4/5 were classified as triple 
negative, with one individual having ER+ disease (Table 3.4). 
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ID corresponds to the assigned patient ID number given to each individual.  For the race 
category, 1R denotes an answer of “White or Caucasian” on a questionnaire asking about 
race, and 3R denotes an answer of “Asian.”  1J indicates that an individual is of 
Ashkenazi Jewish descent, and 13J indicates that an individual is unsure of whether she is 
of Ashkenazi Jewish descent.   
 
 
 
 
 
 
 
 
 
 
  
Table 3.1. Sporadic individual demographic information. 
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Table 3.2. Sporadic individual breast cancer history. 
 
ID corresponds to the patient ID number assigned to each individual.  “Age diag” 
indicates the age at which a woman was first diagnosed with breast cancer.  BC= Breast 
Cancer.  A score of 1 under the BC category indicates the breast cancer was invasive, a 
score of 2 indicates pre-invasive breast cancer (Ductal Carcinoma In Situ, or DCIS), and 
13 indicates type of breast cancer is unknown.  LyNo stands for Lymph Nodes; in the 
LyNo column, a score of 0 indicates no lymph node involvement, a score of 1 indicates 
lymph node involvement, and a score of 13 indicates the patient is unsure of whether 
there was lymph node involvement.  If a patient had lymph node involvement, the 
number of lymph nodes (#LyNo) is indicated in the next column, if known.  ER, PR, and 
Her2 positivity are denoted by a “+” symbol.  In the Surgery column (Surg), 1= 
lumpectomy, 2= mastectomy, and 3= bilateral mastectomy.  If the patient had bilateral 
mastectomy, a score of 1 in the Preventative column (Prevt) indicates the procedure was 
done prophylactically for one breast.  In the treatment category (Rx), R= radiation 
therapy, C= chemotherapy, B= biologic therapy, and H indicates hormonal therapy.  In 
the 2DiagBC column, a score of 1= a patient who has had a second breast cancer, and 0= 
a patient who has not had a second breast cancer.  In terms of second breast cancer type, a 
score of 1 means the second breast cancer was invasive.  The presence (1) or absence (0) 
of metastatic breast cancer (MBC) and treatment for the metastatic breast cancer 
(RxMBC, C= chemotherapy, H= hormonal therapy) are also documented. 
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ID corresponds to the assigned patient ID number given to each individual.  For the race 
category, 1R denotes an answer of “White or Caucasian” on a questionnaire asking about 
race.  11R? 1H means a woman answered “yes” to the question “Are you Hispanic or 
Latino?”  1J indicates that an individual is of Ashkenazi Jewish descent. 
 
 
 
 
 
 
 
  
Table 3.3. BRCA1 individual demographic information. 
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ID corresponds to the patient ID number assigned to each individual.  Age diag indicates 
the age at which a woman was first diagnosed with breast cancer (NA indicates an 
individual who has not been diagnosed with cancer).  BC stands for Breast Cancer.  A 
score of 1 under the BC category indicates the breast cancer was invasive, a score of 0 
indicates the individual has not been diagnosed with breast cancer.  LyNo stands for 
Lymph Nodes; in the LyNo column, a score of 0 indicates no lymph node involvement. 
ER, PR, and Her2 positivity are denoted by a “+” symbol.  In the Surgery column (Surg), 
1= lumpectomy, 2= mastectomy, and 3= bilateral mastectomy.  If the patient had bilateral 
mastectomy, a score of 1 in the Preventative column (Prevt) indicates the procedure was 
done prophylactically for one breast.  In the treatment category (Rx), R= radiation 
therapy, C= chemotherapy, B= biologic therapy, and H indicates hormonal therapy.  In 
the 2DiagBC column, a score of 1= a patient who has had a second breast cancer, and 0= 
a patient who has not had a second breast cancer.  In terms of second breast cancer type, a 
score of 1 means the second breast cancer was invasive.  The presence (1) or absence (0) 
of metastatic breast cancer (MBC) and treatment for the metastatic breast cancer 
(RxMBC, C= chemotherapy, H= hormonal therapy) are also documented. 
 
  
Table 3.4. BRCA1 individual breast cancer history. 
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ID corresponds to the assigned patient ID number given to each individual.  For the race 
category, 1R denotes an answer of “White or Caucasian” on a questionnaire asking about 
race. 
Table 3.5. BRCA2 individual demographic information. 
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The mean age among BRCA2 carrier individuals was 42.2 +/- 7.47 years, and this was 
not younger than the mean age of sporadic individuals or of BRCA1 individuals (Table 
3.5, one-way ANOVA).  Of the ten BRCA2 carriers, five had developed breast cancer at 
the time of sampling, with a mean age at diagnosis of 38.8 +/- 7.85 years (Table 3.6).  
The age of onset in BRCA2 individuals was not significantly different as compared to 
age of onset of sporadic breast or compared to age of onset of BRCA1 cancer among our 
sample population.  Of those BRCA2 carriers who developed cancer, one had confirmed 
lymph node involvement, and 4 out of 5 carriers were classified as ER+, with one 
individual having triple negative breast cancer (Table 3.6). 
The mean age among individuals who developed familial breast cancer was 53 +/- 
5.63 years, and this was significantly older than the mean age of BRCA2 individuals, but 
was not different from the mean ages of sporadic or BRCA1 individuals (Table 3.7, one-
way ANOVA).  The mean age at diagnosis among those who developed familial breast 
cancer was 43.67 +/- 6.91, and this did not differ from the age of onset in sporadic, 
BRCA1, or BRCA2 individuals who developed cancer (one-way ANOVA).  The 
majority of familial cancer patients (8 out of 9 patients) had ER+ disease, and one of 
these individuals had lymph node involvement.  The remaining individual developed 
triple negative breast cancer (Table 3.8).  For relative information and reproductive 
histories of sporadic, familial, and BRCA individuals used in this study, see Appendix.  
Peripheral blood from ten healthy individuals encompassing the age range of all 
patient samples was obtained from the Komen Tissue Bank (age range of normal 
controls: 25-70).  Importantly, because of potential environmental influences on telomere  
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ID corresponds to the patient ID number assigned to each individual.  Age diag indicates 
the age at which a woman was first diagnosed with breast cancer (NA indicates an 
individual has not been diagnosed with breast cancer).  BC stands for Breast Cancer.  A 
score of 0 under the BC category means no breast cancer, 1 indicates the breast cancer 
was invasive, a score of 2 indicates pre-invasive breast cancer (Ductal Carcinoma In Situ, 
or DCIS), and 13 indicates type of breast cancer is unknown.  LyNo stands for Lymph 
Nodes; in the LyNo column, a score of 0 indicates no lymph node involvement, a score of 
1 indicates lymph node involvement, and a score of 13 indicates the patient is unsure of 
whether there was lymph node involvement.  If a patient had lymph node involvement, 
the number of lymph nodes (#LyNo) is indicated in the next column, if known.  ER, PR, 
and Her2 positivity are denoted by a “+” symbol.  In the Surgery column (Surg), 1= 
lumpectomy, 2= mastectomy, and 3= bilateral mastectomy.  If the patient had bilateral 
mastectomy, a score of 1 in the Preventative column (Prevt) indicates the procedure was 
done prophylactically for one breast.  In the treatment category (Rx), R= radiation 
therapy, C= chemotherapy, B= biologic therapy, and H indicates hormonal therapy.  In 
the 2DiagBC column, a score of 1= a patient who has had a second breast cancer, and 0= 
a patient who has not had a second breast cancer.  In terms of second breast cancer type, a 
score of 1 means the second breast cancer was invasive.  The presence (1) or absence (0) 
of metastatic breast cancer (MBC) and treatment for the metastatic breast cancer 
(RxMBC, C= chemotherapy, H= hormonal therapy) are also documented. 
 
 
 
 
 
Table 3.6. BRCA2 individual breast cancer history. 
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ID corresponds to the assigned patient ID number given to each individual.  For the race 
category, 1R denotes an answer of “White or Caucasian” on a questionnaire asking about 
race. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.7. Familial individual demographic information. 
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ID corresponds to the patient ID number assigned to each individual.  Age diag indicates 
the age at which a woman was first diagnosed with breast cancer.  BC stands for Breast 
Cancer.  A score of 1 under the BC category indicates the breast cancer was invasive, a 
score of 2 indicates pre-invasive breast cancer (Ductal Carcinoma In Situ, or DCIS), and 
13 indicates type of breast cancer is unknown.  LyNo stands for Lymph Nodes; in the 
LyNo column, a score of 0 indicates no lymph node involvement, a score of 1 indicates 
lymph node involvement, and a score of 13 indicates the patient is unsure of whether 
there was lymph node involvement.  If a patient had lymph node involvement, the 
number of lymph nodes (#LyNo) is indicated in the next column, if known.  ER, PR, and 
Her2 positivity are denoted by a “+” symbol.  In the Surgery column (Surg), 1= 
lumpectomy, 2= mastectomy, and 3= bilateral mastectomy.  If the patient had bilateral 
mastectomy, a score of 1 in the Preventative column (Prevt) indicates the procedure was 
done prophylactically for one breast.  In the treatment category (Rx), R= radiation 
therapy, C= chemotherapy, B= biologic therapy, and H indicates hormonal therapy.  In 
the 2DiagBC column, a score of 1= a patient who has had a second breast cancer, and 0= 
a patient who has not had a second breast cancer.  In terms of second breast cancer type, a 
score of 1 means the second breast cancer was invasive.  The presence (1) or absence (0) 
of metastatic breast cancer (MBC) and treatment for the metastatic breast cancer 
(RxMBC, C= chemotherapy, H= hormonal therapy) are also documented. 
 
 
 
 
 
 
Table 3.8. Familial individual breast cancer history. 
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DNA from peripheral blood leukocytes of healthy individuals was obtained for age-
matching.  Healthy control individuals had no first degree relatives with cancer history, 
were within the normal BMI (body mass index) range of 18.5 to 24.9 (with the exception 
of the 70 year old individual, as no sample within normal BMI range was available for 
this age), and had never used tobacco (www.cancer.org). 
Table 3.9. Healthy control demographic information. 
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length (Kim, Parks et al. 2009), none of the control individuals had ever used tobacco, 
and all except one (age 70, BMI 33.1) were within the BMI range considered normal 
(Table 3.9). 
 
Patient samples show a trend toward shorter telomere length in BRCA1 carriers 
Using TRF analysis and 3-4 independent replicates per patient sample, average 
telomere lengths were calculated for each patient sample and for normal controls as 
described in Materials and Methods (Figure 3.1, as an example).  Telomeric DNA from 
the peripheral blood leukocytes used in this study yielded a relatively tight distribution of 
telomeric DNA for the majority of samples when run on a gel.  Variability among 
technical replicates for each sample was relatively small.  We did, however, see a wide 
range of telomere lengths within each group;  though we saw a trend toward shorter 
telomere length in BRCA1 carriers compared to normal, sporadic, BRCA2, and familial 
individuals, this result did not reach statistical significance (Figure 3.2, including 
telomere length range in kb within each group).    
 
BRCA1 and BRCA2 individuals show deregulation of telomere-associated genes  
Unsupervised hierarchical clustering of telomere and telomerase-associated genes 
revealed three major groups of genes: those overexpressed in BRCA1 and BRCA2 
individuals, those overexpressed only in BRCA1 individuals, and those not differentially 
expressed among BRCA and sporadic individuals (Figure 3.3).  A comparison of gene 
expression in BRCA1 individuals versus all other individuals (BRCA2, familial, and 
sporadic) found differential expression of 46 genes (p < 0.05).  Notably, 44 out of 46 
genes in this dataset yielded with this analysis were overexpressed, with only two genes, 
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Figure 3.1. Telomeres of age-matched samples and normal control. 
DNA was digested and used for TeloTAGGG analysis as described in Materials and 
Methods.    
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Figure 3.2. BRCA1 patient samples show a trend towards having the shortest 
telomeres. 
Averages telomere lengths were calculated for each sample and normal control, and 
averages + SEM were calculated for each of the 5 groups (normal samples ranging in age 
from 25-70 were included as one group).  The TRF range (in kb) for each group is listed 
below the chart.  The sporadic breast cancer group showed the greatest range in telomere 
lengths, followed by the BRCA1 group. 
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IGFBP2 and SERPINE1/PAI-1 gene, being underexpressed in BRCA1 individuals 
compared to all others.  The top hit was the PPP2R5C gene, which encodes for PP2A, or 
protein phosphatase 2A, a serine/threonine phosphatase involved in negative control of 
cell growth and division (p= 0.000647, 1.43 fold increase vs all others).  Fold change 
values ranged from a 1.54 fold increase in TINF2 (TIN2) expression to a 1.24 fold 
decrease in IGFBP2 expression.  For the complete list of differentially expressed genes in 
BRCA1 individuals compared to all other individuals, see Table 3.10. 
We next separated BRCA1 individuals into those who had a cancer diagnosis at 
time of sampling, and those who did not, and compared each of these groups.  A 
comparison of gene expression in BRCA2 individuals versus all other individuals 
(BRCA1, familial, and sporadic) showed underexpression of 8 genes, with the top hit 
being UPF3A (p value= 0.00785, 1.20 fold decrease vs all others).  Fold change values 
ranged from a 1.18 fold decrease in PPP2R3A expression to a 1.34 fold decrease in 
CDK5R2 expression.  The complete list of telomere-associated genes underexpressed in 
BRCA2 individuals compared to all others is shown in Table 3.11.  Interestingly, only 3 
genes overlap between Tables 3.10 and 3.11, with UPF3A being significantly 
underexpressed in both BRCA1 and BRCA2 individuals, and CHFR and TTC21B being 
overexpressed in BRCA1 individuals but underexpressed in BRCA2 individuals (Tables 
3.10 and 3.11). 
When grouping all BRCA individuals (BRCA1 and BRCA2 with and without a 
cancer diagnosis) and comparing them with sporadic and familial cancer individuals 
using a p value cut-off of p < 0.05, we see differential expression of 83 out of 291 
analyzed telomere-associated genes.  All 83 genes identified in this analysis were  
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Figure 3.3. Unsupervised hierarchical clustering of expression of telomere and telomerase-associated genes reveals three distinct gene clusters. 
Distinct gene clusters are denoted by blue boxes.  From left to right, the first cluster shows genes not differentially expressed among sporadic, familial, and 
BRCA individuals.  The second cluster highlights genes overexpressed in BRCA1 and BRCA2 individuals, and the third cluster highlights genes 
overexpressed only in BRCA1 individuals.  
9
9
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Significantly overexpressed genes from the third cluster of the heat map from Figure 3.1.
Table 3.10. Significant expression changes in telomere and telomerase-
associated genes in BRCA1 individuals vs sporadic, BRCA2, and familial 
individuals. 
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overexpressed in BRCA individuals compared to sporadic and familial individuals.  5 
genes (PECR, SOD1, HSP90AB1, RPL5, and SOAT1) show highly significant 
overexpression, with p values of p < 0.001, and 26 additional genes have p values of p < 
0.01 (Table 3.12).   
We next compared gene expression in BRCA1 individuals to gene expression in 
all non-BRCA individuals (BRCA1 vs sporadic and familial).  Using this analysis, and a 
p-value cut-off of p < 0.05, 85 genes were differentially expressed in BRCA1 vs non-
BRCA individuals (Table 3.13).  All expression changes, with the exception of 
SERPINE1 (p= 0.0350, 1.21 fold decrease), were overexpression.  As was the case with 
the analysis of BRCA1 individuals vs all other individuals, the PPP2R5C gene was the 
top hit (p= 0.000222, 1.5 fold increase).  Next, we compared gene expression in BRCA2 
individuals to gene expression in all non-BRCA individuals (BRCA2 vs sporadic and 
familial).  Using this analysis, we found 31 genes that were differentially expressed 
(Table 3.14), with the vast majority (27 out of 31) of genes being overexpressed.   
 
Analysis of Genes within 1000kb of the Telomere 
Next, expression of genes within 1000 kb of the telomere was accessed in 
BRCA1, BRCA2, sporadic, and familial samples using previously published GEO dataset 
GSE6799.  Unlike in the analysis of telomere and telomerase-associated genes, there is 
no clear pattern of clustering based on BRCA status, though clusters of overexpressed 
genes are more evident in some BRCA1 and BRCA2 individuals as compared to sporadic 
or familial individuals (Figure 3.4).  Among genes in this dataset, a total of 46 genes were  
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Table 3.11. Significant gene expression changes in 
telomere and telomerase-associated genes in 
BRCA2 individuals vs BRCA1, sporadic, and 
familial. 
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Table 3.12. Significant gene expression changes in telomere and telomerase-
associated genes in BRCA individuals vs sporadic and familial individuals. 
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Table 3.13. Significant gene expression changes in telomere and 
telomerase-associated genes in BRCA1 individuals vs non BRCA 
individuals (sporadic and familial). 
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overexpressed in BRCA1 individuals compared to the other groups (sporadic, familial, 
BRCA2), with significance values of p < 0.05, with p < 0.01 for 8 genes, and p < 0.001 
for one gene (Table 3.15).  As was the case in the telomere and telomerase-associated 
 gene dataset, the top hit was PP2A, and PPP2CB, the catalytic subunit of PP2A, was 
also overexpressed in BRCA1 individuals compared to all others.  Next, expression 
profiles were compared for genes in the GSE6799 dataset among BRCA1 individuals 
who had developed breast cancer at time of sampling, and those who had not, and 20 
genes were found to be deregulated in BRCA1 individuals with cancer compared to 
BRCA1 individuals without cancer (Table 3.16).  Of the 20 genes, the majority (19 out of 
20) were underexpressed, and one gene, SERPINE1, was overexpressed.  As mentioned 
previously, SERPINE1 was one of only two genes underexpressed in an analysis of 
BRCA1 individuals vs sporadic, BRCA2, and familial individuals.  The gene set in Table 
3.16 is relatively unique in that the vast majority is underexpressed, and genes 
deregulated in Tables 3.15 and 3.16 only had one gene in common: CERC5.  While 
CECR5 was overexpressed in BRCA1 individuals compared to all other patient samples, 
the gene was significantly underexpressed in BRCA1 individuals who developed cancer 
compared to BRCA1 individuals who did not develop cancer. 
In the BRCA2 group compared to all others, 14 genes were differentially 
expressed, with the majority (9 out of 14) being overexpressed (Table 3.17).  The only 
overlap between the BRCA1 and BRCA2 groups when comparing each to all other 
patient samples was overexpression of SOD1, a superoxide dismutase.  A comparison of 
BRCA2 individuals who developed breast cancer versus those who did not develop breast 
cancer yielded 14 differentially expressed genes, with 10 out of 14 being underexpressed  
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Figure 3.4. Heat map showing expression of genes from GSE6799 in all patient samples. 
1
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Table 3.14.  Expression analysis from genes in 
GSE6799 dataset in BRCA1 individuals vs 
sporadic, BRCA2, and familial.  
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Table 3.15. Expression analysis of genes from 
GSE6799 dataset comparing BRCA1 
individuals who developed cancer vs BRCA1 
individuals who did not develop cancer. 
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(Table 3.18).  CYP2E1 was underexpressed in both BRCA1 individuals with cancer and 
BRCA2 individuals with cancer, but no other genes were found to be commonly 
deregulated in comparing Tables 3.16 and 3.18.  A comparison of BRCA1 individuals 
with cancer vs BRCA2 individuals with cancer found ten genes overexpressed in BRCA1 
cancer individuals, including shelterin components TRF2 and POT1 (Table 3.19).  
Interestingly, no differences were seen in expression of the genes analyzed when 
comparing familial (individuals with a family history but no known BRCA1 or BRCA2 
mutation) compared to all others (data not shown).  
 
Discussion 
Previous studies have correlated expression of telomere-associated genes with 
telomere length in cancer.  One such recent study in breast cancer found an inverse 
relationship between expression of shelterin components TRF1, TRF2, TIN2, and POT1 
and telomere length.  The authors also provide evidence that shelterin components may 
be stimulated by mediators of stress and inflammation in cell culture models.  This study 
used a quantitative PCR-based measurement of telomere content, focused primarily on 
ER+ cancers, and did not investigate the influence of BRCA status (Butler, Hines et al. 
2012).  Interestingly, this study found no correlation between TERT mRNA levels and 
telomere length in breast tumors. 
Similarly, we found increased expression of several telomere and telomerase-
associated genes, but not increased expression of TERT, in a comparison of BRCA1 
individuals vs all other patient samples.  In particular, we saw overexpression of shelterin 
components TIN2, TRF1, and TRF2 in BRCA1 individuals vs all other patient samples in 
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both a comparison using telomere-associated genes and a comparison using genes in the 
GSE6799 dataset.  TIN2, TRF1, and TRF2 are all negative regulators of telomere length 
(Kim, Kaminker et al. 1999; Smogorzewska, van Steensel et al. 2000), and ingenuity 
pathway analysis confirmed the top pathway overexpressed in BRCA1 carriers was 
related to telomere length (data not shown). Among those genes related to control of 
telomere length, we see upregulation of PINX1, or Pin2/TRF1-interacting protein.   
PINX1 is recruited to the telomere by TRF1 and is thought to act as an 
endogenous inhibitor of telomerase activity (Soohoo, Shi et al. 2011).  Among BRCA1 
carriers compared to all other patient samples, we see upregulation of a number of cyclins 
and members of the PI3K/Akt pathway, including NFKB1.  In addition to telomere 
length and cell cycle regulators, we also saw upregulation of interferon stimulated gene 
15 (ISG15).  Lou and colleagues report ISG15 expression is regulated by telomere length, 
with an increase in ISG15 expression in human cell lines as telomeres shorten (Lou, Wei 
et al. 2009). 
In contrast, BRCA2 carriers did not show deregulation of shelterin components in 
any comparison performed.  In accessing BRCA1 carriers with cancer compared to 
BRCA2 carriers without cancer using genes in the GSE6799 dataset, we saw 
overexpression of POT1 and TIN2 in the BRCA1 carriers (Table 3.19).  Generally, 
BRCA1 carriers showed overexpression of genes in this analysis.  In a comparison of 
BRCA1 carriers who developed cancer compared to BRCA1 carriers who did not 
develop cancer, however, those who developed cancer showed almost exclusively 
underexpression of a particular subset of genes (Table 3.16).  
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Table 3.16. Significant expression changes 
among genes in GSE6799 for BRCA2 
individuals vs all others (sporadic, BRCA1, and 
familial). 
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Table 3.17. Significant gene expression 
changes in genes from GSE6799 among 
BRCA2 individuals with cancer vs BRCA2 
individuals without cancer. 
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Table 3.18.  Significant expression changes in 
genes in GSE6799 in a comparison of BRCA1 
with cancer vs BRCA2 with cancer. 
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Our study employed a TeloTAGGG, Southern blot method of determining 
telomere length, which has some advantages over a quantitative PCR-based method.  For 
instance, we are able to visualize and quantify the entire distribution of the telomere 
length and calculate an average length, whereas PCR-based methods are biased towards 
measurements of only the shortest telomeres in a sample population.  This method does 
have its limitations, however, and gel to gel variation may be seen.  In an attempt to 
mitigate this problem, the telomere length from each patient sample was measured 3-4 
times and an average telomere length with standard deviation was calculated.  Another 
drawback of this study is the small sample size for analysis, owing in part to the difficulty 
of obtaining samples from BRCA individuals.  The small sample size contributed to the 
large degree of variability seen in telomere length within each sample grouping.  In 
addition, the study is limited in that the normal controls used for comparison of telomere 
length were not from patient family members.  Thus, despite efforts to control for 
smoking, BMI, and family history of breast cancer in the normal sample set, additional 
environmental influences may have played a role in determining normal telomere length.  
It would also have been ideal to use gene expression analysis from a true normal sample 
for comparison to our BRCA, sporadic, and familial patient samples.  Nevertheless, this 
study provides important insights into how BRCA tumors differ molecularly from other 
breast cancer subtypes, and how those differences might contribute to telomere 
dysfunction and high levels of genomic instability.  In addition, this work sheds light on 
previously uncharacterized differences between BRCA1 and BRCA2 tumors with 
relation to telomere and telomerase-associated genes and telomere-proximal genes.   
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Materials and Methods 
1. Collection of patient blood samples 
Following Institutional Review Board (IRB) approval (IRB # 1011003798; PI: Dr. Lida 
Mina) 10cc of peripheral blood was collected from 40 women (BRCA1, n=10; BRCA2, 
n=10; hereditary breast cancer without BRCA (FAM), n=9; and sporadic breast cancer 
(SPO), n=11).  5 BRCA1 and 5 BRCA2 samples were from women who had not 
developed cancer. 
2. Acquisition of normal blood samples from Komen tissue bank 
Following IRB approval (IRB # 1206009001), freeze-dried DNA extracted from 
peripheral blood of 10 healthy women was obtained from the Komen Tissue Bank at the 
IU Simon Cancer Center.  DNA was resuspended in buffer AE (Qiagen, Valencia, CA) to 
yield a final concentration of 0.5 μg/μL and used in TeloTAGGG assays. 
 
3. DNA extraction from peripheral blood lymphocytes 
Genomic DNA was extracted from peripheral blood mononuclear cells using the DNeasy 
blood and tissue kit with some modifications to the manufacturer’s protocol (Qiagen, 
Valencia, CA).  Specifically. 400 µL of whole blood was incubated for 2 minutes at room 
temperature with 40 µL proteinase K and 8 µL 100 mg/mL RNase A.  400 µL of Buffer 
AL was added to each sample and samples were vortexed and incubated for 10 minutes at 
56°C.  Next, 400 µL 100% ethanol was added and each sample was mixed by vortexing.  
Approximately 1/4 of the mixture for each sample was applied to a DNeasy mini spin 
column placed in a 2 mL collection tube and spun at full speed for 1 minute.  The flow 
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through and collection tube were discarded, and the remaining 3/4 of the mixture for each 
sample was applied to the same collection tube in three additional spins to obtain highly 
concentrated DNA samples.  The remainder of the procedure was followed according to 
the manufacturer’s protocol, and each sample was eluted in 40 µL Buffer AE.  DNA 
concentration and quality was determined using a NanoDrop 2000 Spectrophotometer.  
4. TeloTAGGG assays of telomere length 
Genomic DNA was digested using Rsa1/Hinf1 to leave telomeric DNA (which do not 
have Rsa1/Hinf1restriction sites).  Digested fragments were separated on a 0.8% agarose 
gel, blotted to a nylon membrane (Roche) using capillary transfer and 20 x SSC 
(Invitrogen) buffer.  Following overnight transfer, DNA was UV-crosslinked to the 
membrane (Spectrolinker) and a non-radioactive DIG-labeled telomeric probe was 
hybridized to the membrane.  The membrane was visualized using chemiluminescence.   
5. Measurement of telomere length and age-adjustment 
Mean TRF lengths were calculated using ImageJ software and TeloRun Excel 
spreadsheet program (Herbert, Hochreiter et al. 2006).  Briefly, a grid of 30 boxes was 
positioned over each lane, and the signal intensity and size (kb) corresponding to each 
box was determined and averaged for each sample lane.  Average telomere length was 
labeled on figures by drawing a line across the lanes as described previously (Hochreiter, 
Xiao et al. 2006). 
6. Gene array analysis 
Following RNA extraction and quality assessment, Illumina® Whole-Genome DASL™ 
microarray (Human Ref-8 BeadChips) analysis was performed.  The raw data was 
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normalized and analyzed using Partek® Genomic Suite. Differentially expressed genes 
were identified using ANOVA analysis.  The Indiana University Bioinformatics Core 
conducted gene array analysis and assisted with identification of differentially expressed 
genes. 
7. Statistical analysis 
Unsupervised hierarchical clustering was used to construct heat maps by the Indiana 
University Bioinformatics Core.  P-values < 0.05 were considered significant. 
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CHAPTER FOUR 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 Personalized, targeted medicines are the preferred standard of care over harsh 
chemotherapies, though these options are not currently available to BRCA1 breast cancer 
patients.  Telomerase inhibition offers a targeted treatment option that may prove less 
toxic than chemotherapy and radiation to most normal cells.  The work presented in this 
thesis suggests that BRCA1 status, baseline telomere length, and expression profiles of 
telomere-associated and telomere-proximal genes are important factors to consider in 
implementing telomerase inhibitor treatment in breast cancer.  We observed enhanced 
sensitivity of BRCA1 mutant breast and ovarian cancer cell lines to clinically relevant 
treatment concentrations of GRN163L, and this sensitivity correlated with shorter 
telomere lengths at baseline and increased expression of -H2AX for BRCA1 mutant 
versus BRCA1 wild-type cell lines.   
This study is novel in that assessment of telomerase inhibitor sensitivity and 
telomere length as a function of BRCA1 status was conducted in established, isogenic 
cell line pairs.  Notably, the HCC1937+BRCA1 and UWB1.289+BRCA1 cell lines were 
created by pooled, as opposed to clonal, selection to stably express BRCA1, thus 
decreasing the likelihood of selection for longer telomere length in the process of cell line 
establishment.  In addition, using an established cell line model to study the relationship 
between BRCA1 and telomerase inhibition has advantages over utilizing transient 
overexpression or knockdown of BRCA1; transient overexpression or knockdown has the 
potential to alter growth kinetics and influence response to telomerase inhibitors due to 
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the cell cycle effects of BRCA1.  Despite these challenges, it would be interesting to test 
the effects of GRN163L in a BRCA1-inducible, or BRCA1 targeted deletion model.   
 Given the differences in baseline telomere length between BRCA1 mutant and 
BRCA1 wild-type cell lines, it stands to reason that BRCA1 mutant cell lines require a 
shorter period of treatment with GRN163L to elicit telomere dysfunction. In an attempt to 
further investigate this possibility, rate of telomere shortening was accessed in BRCA1 
mutant and BRCA1 wild-type cell lines over a three or six week period.  In general, 
UWB1.289 and UWB1.289+BRCA1 cell lines, which had longer telomeres at baseline 
compared to the HCC1937 pBp and HCC1937+BRCA1 cell line pair, also showed a 
faster rate of telomere shortening, with rates in the UWB1.289 cell pair nearly double the 
rates in the HCC1937 cell line pair.  Though each BRCA1 wild-type cell line showed a 
slightly higher rate of base pair loss per week as compared to the BRCA1 mutant cell 
line, this result is difficult to interpret as telomere shortening in the cell lines accessed 
was not a linear process.  For instance, the UWB1.289 cell line initially showed telomere 
shortening at an accelerated rate compared to the UWB1.289+BRCA1 cell line, but 
showed a degree of recovery by week three that was not seen in the UWB1.289+BRCA1 
cell line.  
This study also investigated the molecular responses to GRN163L treatment in 
BRCA1 mutant and BRCA1 wild-type cell lines through accessing cell cycle changes and 
expression of DNA double-strand break marker -H2AX.  Though no cell cycle changes 
were seen following GRN163L treatment, induction of -H2AX in BRCA1 mutant cells 
compared to BRCA1 wild-type cells was seen as early as one week following initiation of 
GRN163L treatment.  Expression of -H2AX persisted in the BRCA1 mutant cell lines, 
120 
 
suggesting an impairment in DNA repair caused by telomerase inhibitor treatment.  
Though -H2AX is a marker of telomere dysfunction, this study did not discern whether 
-H2AX was present at the telomere, and this assessment would be important to future 
studies. 
Despite using four different cell lines with mutations from various regions in the 
full-length BRCA1 gene, the contributions of specific types of mutations in determining 
sensitivity to GRN163L could not be delineated.  One exception to this may be the 
observation that SUM149PT cells, which harbor an acquired somatic mutation in 
BRCA1, do not show sensitivity to GRN163L in clonogenic survival assay after three- 
week treatment (Figure A1).  In contrast, the BRCA1 mutations in HCC1937 pBp and 
UWB1.289 cells, though from different regions of the BRCA1 gene, are pathogenic, 
germline mutations resulting in frameshifts and protein inactivation.   
Based upon the findings presented in Chapter Two and from recent work 
suggesting BRCA1 carriers harbor shorter telomeres at baseline compared to other breast 
cancer subtypes, telomerase inhibition may be a viable treatment option for BRCA1 
cancer patients, either alone or in combination with DNA damaging agents.  This work 
demonstrates BRCA1 acts synergistically with doxorubicin, a commonly used drug in 
treatment of breast cancer.  Thus, combination treatment with doxorubicin and GRN163L 
may lower the effective dose of doxorubicin required to elicit a patient response.  In 
addition, GRN163L pretreatment for a six-week period, following by addition of 
cisplatin, showed a greater effect compared to cisplatin treatment alone.  Thus, cells with 
shortened telomeres are more sensitive to cisplatin, and this result has been reported by 
others (Uziel, Beery et al. 2010).  For this reason, treatment with telomerase inhibitors 
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prior to chemotherapy may minimize the treatment duration and, thus, the toxic side 
effects of chemotherapy.  This finding has broad-ranging implications that may extend to 
all cancers that express telomerase.   
Other homologous recombination factors that act in concert with BRCA1, 
including NBS1, Rad51, and BRCA1, genes with known roles in telomere maintenance, 
are mutated in a proportion of hereditary breast and ovarian cancers.  It would be 
interesting to access baseline telomere lengths in these individuals and to determine 
sensitivity to telomerase inhibition in these genetic backgrounds.  In addition, triple 
negative breast cancer cells have what has been described as a “BRCAness” phenotype, 
and may also be sensitive to telomerase inhibition.  This study also raises questions about 
considering expression profiles of shelterin components in predicting baseline telomere 
length and response to chemotherapy and/or telomerase inhibition, General 
overexpression of telomere and telomerase-associated genes and of genes within 1000 kb 
of the telomere was observed in BRCA1 carriers and, to a lesser degree, in BRCA2 
carriers.  Notably, deregulated genes were almost exclusively overexpressed in BRCA1 
individuals, and several of these genes have known roles in regulation of telomere length. 
Based on the results presented in Chapters Two and Three and in studies from 
others, we propose a model by which shorter telomere lengths in BRCA1 mutant cancer 
cell lines at baseline, coupled with additional effects of BRCA1 loss or 
haploinsufficiency on telomere dysfunction and ability to repair DNA damage, lead to a 
shorter time required to cause telomere dysfunction in BRCA1 mutant cancer cell lines 
compared to BRCA1 wild-type cancer cell lines.  Once telomere dysfunction is elicited in 
BRCA1 mutant cell lines, we propose that it is persistent and contributes to the high    
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Figure 4.1. Proposed mechanism of action of GRN163L in BRCA1 mutant and 
wild-type cell lines. 
Based on the results of this thesis, we propose a model in which BRCA1 mutant cells 
have shorter telomere lengths (orange) at baseline, due to overexpression of negative 
regulators of telomere length, and increased genomic and telomeric instability owing to 
the loss of the tumor suppressive function of wild-type BRCA1.  This shorter telomere 
length (orange) makes BRCA1 mutant cells more susceptible to telomere dysfunction 
(red) following telomerase inhibitor treatment.  In addition, since BRCA1 mutant cells 
are dysfunctional in the error-free repair of double strand breaks via homologous 
recombination, DNA damage elicited by telomerase inhibitors either persists, 
unrepaired, or is repaired by error-prone NHEJ, further contributing to genomic 
instability through facilitating formation of abnormal telomere structures. 
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 degree of genomic instability that characterizes the BRCA1 cancer subtype (Figure 4.1).  In 
addition, factors that may contribute to telomere dysfunction through accelerating telomeric 
loss are already present in BRCA1 mutant individuals (and BRCA1 carriers) as has been 
reported previously by others, and as the data presented in Chapter Three of this thesis 
suggests. 
 Future work should focus on further understanding the molecular responses to 
GRN163L in BRCA1 mutant cell lines through studying additional factors involved in 
telomere dysfunction, such as 53BP1.  It would be interesting to determine whether the 
sensitivity to GRN163L seen in BRCA1 mutant cancer cell lines also occurs in BRCA1 
carrier populations or in BRCA2 cancer or cancer populations.  This research suggests loss of 
one copy of BRCA1 leads to overexpression of negative regulators in telomere length.  It is 
tempting to hypothesize that this overexpression acts as a compensatory homeostasis 
mechanism to keep cell growth in check in BRCA1 haploinsufficient cells.  We hypothesize 
wild-type BRCA1 acts as a tumor suppressor and component of telomere maintenance 
through two general mechanisms (Figure 4.2, proposed mechanism):  
(1) Prior to telomere dysfunction, BRCA1 maintains a balance in expression levels of 
shelterin components that negatively regulate telomere length, in effect ensuring 
formation of the t-loop structure and protection of the telomere from DNA repair 
machinery; (2) BRCA1 mutation leads to overexpression of shelterin components; this 
imbalance tips the scales in favor of telomere shortening, resulting in telomere shortening 
and ultimately, telomere uncapping and activation of a DNA damage response at the 
telomere.  Because BRCA1 is central to the error-free homologous repair of double-
strand breaks, BRCA1 mutant cells attempt to repair telomere dysfunction via NHEJ, 
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resulting in fusion of nonhomologous chromosomes and additional chromosomal 
aberrations involving the telomere.  Furthermore, loss of BRCA1 function leads to 
dysfunctional cell cycle checkpoints.  In particular, BRCA1 mutant cells are unable to 
halt the cell cycle at the G2/M checkpoint, which is normally activated after telomere 
dysfunction.  Additionally, BRCA1 is recruited to sites of double strand breaks by the 
MRN complex and is thought to be involved in generation of the single-stranded DNA 
required for homologous recombination (Chen, Nievera et al. 2008).  It is possible that 
the MRN complex, which interacts with shelterin components at the telomere and is 
important for the formation of the single-stranded G overhang, also recruits BRCA1 to 
the telomere to facilitate this function (Deng, Guo et al. 2009), and this model has been 
proposed by others (Eliot Rosen, in press). In conclusion, this work supports 
consideration of BRCA1 status, baseline telomere length, and expression of telomere and 
telomerase-associated genes in individualized treatment plans in hereditary breast cancer, 
and also potentially in other cancer types.   
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Figure 4.2. Proposed mechanism of action of BRCA1 at the telomere. 
We hypothesize wild-type BRCA1 acts as a tumor suppressor and component of 
telomere maintenance through two general mechanisms: (A) Prior to telomere 
dysfunction, BRCA1 maintains a balance in expression levels of shelterin components 
that negatively regulate telomere length, in effect ensuring formation of the t-loop 
structure and protection of the telomere from DNA repair machinery.  (B)  BRCA1 
mutation leads to overexpression of shelterin components; this imbalance tips the scales 
in favor of telomere shortening, resulting in telomere shortening and ultimately, 
telomere uncapping and activation of a DNA damage response at the telomere.  
Because BRCA1 is central to the error-free homologous repair of double-strand breaks, 
BRCA1 mutant cells attempt to repair telomere dysfunction via NHEJ, resulting in 
fusion of nonhomologous chromosomes and additional chromosomal aberrations 
involving the telomere. 
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APPENDIX 
 
 
 
Figure A1. SUM149PT cells are not significantly affected by 3 week treatment with 
GRN163L. 
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TabTalb 
 
ID indicates the patient number assigned to each individual.  A score of 0 in the Blood 
relative column indicates an individual with no family relative who has or has had breast 
or ovarian cancer, and a score of 1 indicates an individual with a blood relative who has 
or has had breast or ovarian cancer.  In the Relative type column, 1= mother, 2= maternal 
grandmother, 3= paternal grandmother, 4= sister, 5= daughter, 6= maternal aunt, 7= 
paternal aunt, 8= maternal first cousin, 9= paternal first cousin, and 10= male blood 
relatives who have or have had breast cancer.  In the cancer location column, 1= the 
relative had breast cancer in 1 breast, 2= the relative had breast cancer in both breasts, 
and 3= ovarian cancer.  If applicable, the age of the relative’s diagnosis is also given. 
 
 
 
 
 
 
 
Table A1. Sporadic individual relative information. 
Appendix 
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ID indicates the patient number assigned to each individual.  Age of menarche is the age 
of first menstrual period, Age FP= age of first pregnancy, a score of 0 in the HRT 
(hormone replacement therapy) column indicates an individual has never taken hormone 
replacement therapy, and 1 indicates an individual who has taken hormone replacement 
therapy.  The Duration of HRT is listed in years, if applicable.  In the Currently on HRT 
category, 0= not currently taking hormones, 1= currently taking hormones.  In the Type 
of HRT column, 1= Estrogen, 2= Estrogen and Progesterone, and 13= patient is unsure of 
type. 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2. Sporadic individual reproductive history. 
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ID indicates the patient number assigned to each individual.  A score of 0 in the Blood 
relative column indicates an individual with no family relative who has or has had breast 
or ovarian cancer, and a score of 1 indicates an individual with a blood relative who has 
or has had breast or ovarian cancer.  In the Relative type column, 1= mother, 2= maternal 
grandmother, 3= paternal grandmother, 4= sister, 5= daughter, 6= maternal aunt, 7= 
paternal aunt, 8= maternal first cousin, 9= paternal first cousin, and 10= male blood 
relatives who have or have had breast cancer.  In the cancer location column, 1= the 
relative had breast cancer in 1 breast, 2= the relative had breast cancer in both breasts, 
and 3= ovarian cancer.  If applicable, the age of the relative’s diagnosis is also given. 
 
 
Table A3. BRCA1 individual relative information. 
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Table  
 
ID indicates the patient number assigned to each individual.  Age of menarche is the age 
of first menstrual period, Age FP= age of first pregnancy, a score of 0 in the HRT 
(hormone replacement therapy) column indicates an individual has never taken hormone 
replacement therapy, and 1 indicates an individual who has taken hormone replacement 
therapy.  The Duration of HRT is listed in years, if applicable.  In the Currently on HRT 
category, 0= not currently taking hormones, 1= currently taking hormones.  In the Type 
of HRT column, 1= Estrogen, 2= Estrogen and Progesterone, and 13= patient is unsure of 
type. 
 
 
 
 
 
 
 
 
Table A4. BRCA1 individual reproductive history. 
Appendix 
131 
 
 
 
 
 
 
 
ID indicates the patient number assigned to each individual.  A score of 0 in the Blood 
relative column indicates an individual with no family relative who has or has had breast 
or ovarian cancer, and a score of 1 indicates an individual with a blood relative who has 
or has had breast or ovarian cancer.  In the Relative type column, 1= mother, 2= maternal 
grandmother, 3= paternal grandmother, 4= sister, 5= daughter, 6= maternal aunt, 7= 
paternal aunt, 8= maternal first cousin, 9= paternal first cousin, and 10= male blood 
relatives who have or have had breast cancer.  In the cancer location column, 1= the 
relative had breast cancer in 1 breast, 2= the relative had breast cancer in both breasts, 
and 3= ovarian cancer.  If applicable, the age of the relative’s diagnosis is also given. 
 
 
Table A5. BRCA2 individual relative information. 
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ID indicates the patient number assigned to each individual.  Age of menarche is the age 
of first menstrual period, Age FP= age of first pregnancy, a score of 0 in the HRT 
(hormone replacement therapy) column indicates an individual has never taken hormone 
replacement therapy, and 1 indicates an individual who has taken hormone replacement 
therapy.  The Duration of HRT is listed in years, if applicable.  In the Currently on HRT 
category, 0= not currently taking hormones, 1= currently taking hormones.  In the Type 
of HRT column, 1= Estrogen, 2= Estrogen and Progesterone, and 13= patient is unsure of 
type. 
 
 
 
 
 
 
 
 
Table A6. BRCA2 individual reproductive history. 
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ID indicates the patient number assigned to each individual.  A score of 0 in the Blood 
relative column indicates an individual with no family relative who has or has had breast 
or ovarian cancer, and a score of 1 indicates an individual with a blood relative who has 
or has had breast or ovarian cancer.  In the Relative type column, 1= mother, 2= maternal 
grandmother, 3= paternal grandmother, 4= sister, 5= daughter, 6= maternal aunt, 7= 
paternal aunt, 8= maternal first cousin, 9= paternal first cousin, and 10= male blood 
relatives who have or have had breast cancer.  In the cancer location column, 1= the 
relative had breast cancer in 1 breast, 2= the relative had breast cancer in both breasts, 
and 3= ovarian cancer.  If applicable, the age of the relative’s diagnosis is also given. 
 
 
 
 
 
 
Table A7. Familial individual relative information. 
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ID indicates the patient number assigned to each individual.  Age of menarche is the age 
of first menstrual period, Age FP= age of first pregnancy, a score of 0 in the HRT 
(hormone replacement therapy) column indicates an individual has never taken hormone 
replacement therapy, and 1 indicates an individual who has taken hormone replacement 
therapy.  The Duration of HRT is listed in years, if applicable.  In the Currently on HRT 
category, 0= not currently taking hormones, 1= currently taking hormones.  In the Type 
of HRT column, 1= Estrogen, 2= Estrogen and Progesterone, and 13= patient is unsure of 
type. 
 
 
 
 
 
Table A8. Familial individual reproductive history. 
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